[{"orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Adjuvant cisplatin-based chemotherapy significantly improves outcomes of completely resected early-stage non-small-cell lung cancer (NSCLC) patients. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "EXPERIMENTAL DESIGN: NSCLC patient-derived xenograft models (n=45) were implanted subcutaneously into panels of nude mice and randomization cohorts were treated with either cetuximab, cisplatin, cisplatin plus cetuximab, vehicle control, or else were left untreated. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Frequency and functional activity of Treg was analyzed in 31 NSCLC stage IB-IIIA patients treated by neoadjuvant Cetuximab/Docetaxel/Cisplatin prior to surgery. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVES: The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) on Day 1 (21-day cycles) plus weekly cetuximab (400 mg/m(2) loading dose, then 250 mg/m(2)) for 4-6 cycles. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Pemetrexed, cisplatin, and cetuximab appeared efficacious and tolerable in advanced nonsquamous NSCLC patients. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OPINION STATEMENT: Twenty years ago, an individual patient data meta-analysis of eight cisplatin-based adjuvant chemotherapy (AC) studies in completely resected early stage non-small cell lung cancer (NSCLC) demonstrated a 13\u00a0% reduction of the risk of death favoring chemotherapy that was of borderline statistical significance (p\u00a0=\u00a00.08). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The purpose of the present study was to investigate the curative effect of different treatment of navelbine plus cisplatin in combination with gefitinib and gefitinib single on gefitinib-resistance advanced NSCLC patients. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "AP regimen (pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous non-small cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Moreover, Pim-1 knockdown sensitized NSCLC cells to cisplatin and EGFR tyrosine kinase inhibitor, gefitinib. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Using in vitro drug-resistant NSCLC cell models, we provide evidence that acquired cisplatin resistance may reduce the sensitivity of cancer cells to subsequent treatment with a molecular-targeted agent. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "excision repair cross-complementation group 1 (ERCC1) - cisplatin] may well also complement NSCLC diagnosis. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatin-based chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemotherapy-na\u00efve patients with advanced/metastatic (stage IIIB/IV) squamous non-small-cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Treatment with the combination of axitinib and cisplatin/gemcitabine demonstrated anti-tumour activity in patients with advanced/metastatic squamous NSCLC and the fatal haemoptysis rate was low. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: We conducted a phase II study to evaluate the efficacy and safety of S-1 plus cisplatin with bevacizumab followed by maintenance bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: S-1 plus cisplatin with bevacizumab is an active and well-tolerated regimen in patients with chemotherapy-na\u00efve non-squamous NSCLC. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, non-small cell lung cancer (NSCLC). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OPINION STATEMENT: Twenty years ago, an individual patient data meta-analysis of eight cisplatin-based adjuvant chemotherapy (AC) studies in completely resected early stage non-small cell lung cancer (NSCLC) demonstrated a 13\u00a0% reduction of the risk of death favoring chemotherapy that was of borderline statistical significance (p\u00a0=\u00a00.08). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (stage IIIB or IV) were randomized to Cisplatin-Paclitaxel (Chemotherapy group, N=112) or Cisplatin-Paclitaxel plus CADI-05 (Chemoimmunotherapy group, N=109). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: There was no survival benefit with the addition of CADI-05 to the combination of Cisplatin-Paclitaxel in patients with advanced NSCLC; however, the squamous cell subset did demonstrate a survival advantage. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "drug": "cisplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Necitumumab is a new anti-EGFR monoclonal antibody that improves survival when combined to cisplatin/gemcitabine chemotherapy and has been approved in first-line advanced NSCLC. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Patients receiving gemcitabine\u00a0+\u00a0platinum as first-line anti-cancer treatment for advanced NSCLC experienced relatively poor QoL scores throughout treatment course. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: This study examines the effect of the cytotoxic drug Gemcitabine and the EGFR tyrosine kinase inhibitor Gefitinib on the expression of NK group 2 member D (NKG2D) ligands as well as the sensitivity of NSCLC cells to the NK-mediated lysis. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: In keeping with the effect on NKG2D expression, Gemcitabine enhanced NK cell-mediated cytotoxicity while Gefitinib attenuated NK cell killing in NSCLC cells. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb~IV NSCLC who received multiple cycles of chemotherapy. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Trials investigating the efficacy and safety of combining molecular targeted agent (MTA) with platinum-gemcitabine (PG) in first-line treatment of advanced non-small cell lung cancer (NSCLC) have shown inconsistent findings. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This phase II study assessed the efficacy and safety of axitinib combined with cisplatin/gemcitabine in chemotherapy-na\u00efve patients with advanced/metastatic (stage IIIB/IV) squamous non-small-cell lung cancer (NSCLC). ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Treatment with the combination of axitinib and cisplatin/gemcitabine demonstrated anti-tumour activity in patients with advanced/metastatic squamous NSCLC and the fatal haemoptysis rate was low. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC). ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer (NSCLC). ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: This study did not meet its primary end point of improved OS when sorafenib was added to first-line gemcitabine/cisplatin in patients with advanced nonsquamous NSCLC. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Our data suggest ABCG2 htSNPs rs2725264 (overall group and taxane-platinum combination group) and rs4148149 (gemcitabine-platinum combination group) were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: ERCC2 htSNPs rs50872 (overall), rs238405 (taxane-platinum doublets group), and rs238416 (gemcitabine-platinum doublets group) and infection related to first-line chemotherapy were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " We assessed the prognostic and predictive value of \u03b2-tubulin III (TUBB3) expression, as determined by immunohistochemistry, in 412 non-small cell lung cancer (NSCLC) specimens from early-stage patients who received neoadjuvant chemotherapy (paclitaxel- or gemcitabine-based) in a phase III trial (IFCT-0002). ", "drug": "gemcitabine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "EXPERT OPINION: Bevacizumab and cetuximab are the most studied mAbs in NSCLC, but only bevacizumab is in clinical practice in the first-line setting. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Moreover, the novel combination of bevacizumab and erlotinib is very promising for the treatment of patients with NSCLC harbouring EGFR mutations. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " INTRODUCTION: Cetuximab and bevacizumab have each been demonstrated to prolong survival when added to chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: We reviewed the electronic records of patients with NSCLC treated with an EGFR inhibitor-based combination regimen: erlotinib and cetuximab; erlotinib, cetuximab and bevacizumab; erlotinib and dasatinib; erlotinib and bortezomib; or cetuximab and sirolimus. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Eight of 34 evaluable patients (24%) with advanced, refractory NSCLC evaluable for response achieved SD \u22656 months/PR (PR=3; SD \u22656 months=5) on EGFR inhibitor-based combination regimens (erlotinib, cetuximab; erlotinib, cetuximab and bevacizumab; and, erlotinib, bortezomib), including patients with secondary resistance to single-agent EGFR inhibitors, resistant mutations, wild-type disease, and, squamous histology. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: The combination of erlotinib, cetuximab, and bevacizumab was well-tolerated and demonstrated antitumor activity in heavily pretreated patients with NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Platinum-based doublet chemotherapy with or without bevacizumab is the standard of care for the initial management of advanced and metastatic non-small cell lung cancer (NSCLC) without a targetable molecular abnormality. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: The bevacizumab plus erlotinib study (BEVERLY) is a randomized, open-label, phase III trial investigating first-line erlotinib plus bevacizumab versus erlotinib in patients with advanced NSCLC harboring activating EGFR mutations. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: If the primary endpoint of PFS is met, the erlotinib plus bevacizumab combination will be confirmed as the best first-line treatment for patients with advanced NSCLC harboring activating EGFR mutations. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "It is concluded that bevacizumab should be reserved only for highly select elderly patients with advanced NSCLC when the clinician deems it useful in the face of acceptable toxicities. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains unknown. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as first-line therapy in patients with advanced NSCLC harboring EGFR gene mutations. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Gefitinib in combination with bevacizumab as first-line therapy seems to be a favorable and well-tolerated treatment for patients with advanced NSCLC with activating EGFR gene mutations, especially those with EGFR exon 19 deletion mutations, although the primary end point was not met because the lower limit of the CI was less than 40%. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Currently, five molecular targeted agents were approved for treatment of advanced NSCLC: Gefitinib, erlotinib and afatinib for positive EGFR mutation, crizotinib for positive echinoderm microtubule-associated protein-like 4 (EML4)-ALK translocation and bevacizumab. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced non-small cell lung cancer (NSCLC), and are currently approved for use in clinical practice. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In NSCLC, OS scores of bevacizumab improved from 0% to 50%, as a result of histology, lower prices, and extended therapy. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In NSCLC, 10 cycles of bevacizumab scored 0%. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Antiangiogenic agents, including the approved vascular endothelial growth factor (VEGF)-targeted monoclonal antibody, bevacizumab, as well as a number of investigational tyrosine kinase inhibitors (TKIs) that simultaneously target multiple angiogenic pathways, have demonstrated activity in patients with NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Bevacizumab (an anti-VEGF agent) is undergoing investigation in clinical trials on brain metastases from non-small cell lung cancer (NSCLC), breast cancer and melanoma. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Bevacizumab, an anti-VEGF recombinant humanized monoclonal antibody, is the first targeted agent which, when combined with chemotherapy, has shown superior efficacy versus chemotherapy alone as first-line treatment of advanced non-squamous NSCLC patients. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This review will focus on the potential role of bevacizumab and other anti-angiogenetic agents in the treatment of brain metastases from NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous non-small-cell lung cancer (NSCLC). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: A panel of expert oncologists, pulmonologists and radiologists reviewed the available data to identify predictive factors for PH in order to help guide physicians using bevacizumab in patients with NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: An individualised risk-benefit assessment should be undertaken in all patients with NSCLC in whom bevacizumab is being considered. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: We aimed to explore the use of platinum plus bevacizumab in a real world NSCLC population. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: We retrospectively collected data from patients affected by NS-NSCLC treated with platinum plus bevacizumab across Tuscany. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor ligand, has shown survival benefits in the treatment of many types of malignant tumors, including non-small-cell lung cancer (NSCLC). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We conducted this systematic review and meta-analysis to investigate the risk of the most clinically relevant adverse events related to bevacizumab in advanced NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We included prospective randomized controlled Phase II/III clinical trials that compared therapy with or without bevacizumab for advanced NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: The addition of bevacizumab to therapy in advanced NSCLC did significantly increase the risk of proteinuria, hypertension, and hemorrhagic events but not arterial/venous thromboembolic events, gastrointestinal perforation, or fatal adverse events. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " INTRODUCTION: Bevacizumab- and pemetrexed-based therapies have demonstrated activity in patients with non-small-cell lung cancer (NSCLC) and nonsquamous histologic features. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: The included patients had stage IIIB (malignant pleural effusion) or IV NSCLC with nonsquamous histologic features, adequate organ function, no contraindications to bevacizumab, and no previous cytotoxic therapy. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " AIM: A study was conducted to determine the overall risk and incidence of hypertension with bevacizumab in non-small-cell lung cancer (NSCLC) patients. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: Whether bevacizumab enhances the effect of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on EGFR mutant non-small cell lung cancers (NSCLCs) remains unknown. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We conducted a phase II trial to investigate the efficacy and safety of gefitinib when combined with bevacizumab as first-line therapy in patients with advanced NSCLC harboring EGFR gene mutations. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Gefitinib in combination with bevacizumab as first-line therapy seems to be a favorable and well-tolerated treatment for patients with advanced NSCLC with activating EGFR gene mutations, especially those with EGFR exon 19 deletion mutations, although the primary end point was not met because the lower limit of the CI was less than 40%. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " The meta-analysis evaluated the efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer (NSCLC). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Chemotherapy or TKIs in combination with bevacizumab significantly prolonged PFS (HRpfs 0.72, 95\u00a0% CIpfs 0.66-0.79, P pfs\u00a0<\u00a00.001) and OS (HRos 0.90, 95\u00a0% CIos 0.82-0.99, P os\u00a0=\u00a00.029) as first-line treatment for NSCLC compared with chemotherapy or TKIs alone. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVES: Platinum-based chemotherapy with bevacizumab is a standard therapy for patients with stage IIIB/IV non-small cell lung cancer (NSCLC) with non-squamous (NS) histology. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Pazopanib has limited activity in NSCLC-NS in patients who have experienced disease progression on bevacizumab. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We aimed to compare the efficacy and safety of the combination of erlotinib and bevacizumab compared with erlotinib alone in patients with non-squamous NSCLC with activating EGFR mutation-positive disease. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: In this open-label, randomised, multicentre, phase 2 study, patients from 30 centres across Japan with stage IIIB/IV or recurrent non-squamous NSCLC with activating EGFR mutations, Eastern Cooperative Oncology Group performance status 0 or 1, and no previous chemotherapy for advanced disease received erlotinib 150 mg/day plus bevacizumab 15 mg/kg every 3 weeks or erlotinib 150 mg/day monotherapy as a first-line therapy until disease progression or unacceptable toxicity. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "INTERPRETATION: Erlotinib plus bevacizumab combination could be a new first-line regimen in EGFR mutation-positive NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVES: ABIGAIL, a phase II, randomized, open-label, multicenter study evaluated the correlation between biomarkers and best overall response (BOR) to bevacizumab with chemotherapy in patients with advanced or recurrent non-small-cell lung cancer (NSCLC). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: A total of 303 patients with NSCLC were randomized to receive bevacizumab 7.5mg/kg or 15mg/kg until progression or unacceptable toxicity (plus six cycles of chemotherapy). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF) that provides a survival benefit to patients with non-small cell lung cancer (NSCLC). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "However, the treatment is sometimes accompanied by life-threatening bleeding events, and studies have not yet identified factors that can predict outcomes for NSCLC patients receiving bevacizumab. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: To identify prognostic factors for patients with NSCLC who are undergoing bevacizumab therapy, this study retrospectively investigated 34 consecutive patients with NSCLC treated with bevacizumab-containing chemotherapy. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: The onset of adverse cardiovascular events during bevacizumab therapy may be a favorable prognostic factor for patients with NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous non-small-cell lung cancer (NSCLC) was evaluated. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: We conducted a phase II study to evaluate the efficacy and safety of S-1 plus cisplatin with bevacizumab followed by maintenance bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: S-1 plus cisplatin with bevacizumab is an active and well-tolerated regimen in patients with chemotherapy-na\u00efve non-squamous NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Bevacizumab leads to improved survival for patients with metastatic colorectal cancer (CRC) or non-small cell lung cancer (NSCLC) when added to chemotherapy. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We examined differences in characteristics and outcomes of patients with CRC and NSCLC cancers who received bevacizumab with chemotherapy versus chemotherapy alone. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Previous studies have demonstrated the efficacy and safety of bevacizumab in the treatment of non-small-cell lung cancer (NSCLC). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Summary data from randomised trials comparing first-line bevacizumab plus platinum-based chemotherapy with chemotherapy alone for inoperable locally advanced, recurrent or metastatic NSCLC were meta-analysed. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Bevacizumab significantly prolonged OS and PFS when added to first-line platinum-based chemotherapy in patients with advanced NSCLC; no unexpected toxicity was evident. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Because vascular endothelial growth factor (VEGF) is the key mediator MPE production, we evaluated the efficacy and safety of chemotherapy plus bevacizumab, an anti-VEGF antibody, in non-squamous NSCLC patients with MPE, especially regarding the control of pleural effusions. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: This is the first study to report that bevacizumab plus chemotherapy is highly effective for the management of MPE in non-squamous NSCLC patients. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Antiangiogenic agents, including the approved vascular endothelial growth factor (VEGF)-targeted monoclonal antibody, bevacizumab, as well as a number of investigational tyrosine kinase inhibitors (TKIs) that simultaneously target multiple angiogenic pathways, have demonstrated activity in patients with NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " To evaluate the efficacy and safety of bevacizumab-containing chemotherapy for non-small cell lung cancer (NSCLC), we performed a population-based observational study. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The efficacy and safety of bevacizumab-containing chemotherapy for NSCLC patients were evaluated at 14 sites (17 hospital departments) in a prefecture of Japan between December 2009 and August 2011. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We deduced that bevacizumab-containing chemotherapy is effective against NSCLC and also tolerable in clinical practice. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, non-small cell lung cancer (NSCLC). ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: From August 2008 to May 2011, consecutive chemo-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) received pemetrexed 500mg/m(2), oxaliplatin 100mg/m(2) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles, in the outpatient setting. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: In this single centre experience, the combination of pemetrexed, oxaliplatin and bevacizumab was well tolerated and had promising activity as first-line therapy in unselected patients with stage IV non-squamous NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The anti-vascular endothelial growth factor (VEGF) monoclonal antibody, bevacizumab, is the only US Food and Drug Administration-approved antiangiogenic agent for advanced NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Accumulated safety data with bevacizumab in NSCLC shows that patients are at risk for hemorrhage, venous thromboembolism, hypertension, and proteinuria. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This review describes the molecular rationale for targeting angiogenic pathways in anticancer therapy and summarizes safety and tolerability data from clinical trials of bevacizumab or aflibercept in combination with chemotherapy and the investigational TKIs and VDAs in patients who have advanced NSCLC. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In particular, in case of WT NSCLC with non-squamous histology, the use of platinum-based combinations including pemetrexed or bevacizumab became the standard treatment and the maintenance therapy with pemetrexed a further opportunity for selected patients. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Platinum-based doublet chemotherapy with or without bevacizumab is the standard of care for the initial management of advanced and metastatic non-small cell lung cancer (NSCLC) without a targetable molecular abnormality. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: In this cohort of patients with advanced NSCLC, patients received a platinum agent with or without bevacizumab or pemetrexed, a TKI, or a single agent. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This review attempts to address three fundamental questions clinicians face in choosing first-line and maintenance treatment for advanced NSCLC, particularly nonsquamous histology: Is pemetrexed or a taxane agent better for combination with platinum therapy? Should bevacizumab be used, and is it beneficial when added to pemetrexed chemotherapy? When is maintenance therapy indicated, and which agent is best?  BACKGROUND: CHFR expression has previously been established as a powerful predictor for response to taxane based first-line chemotherapy in non-small cell lung cancer. ", "drug": "Bevacizumab", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: This multicentre, open-label, randomized, controlled phase II study evaluated cilengitide in combination with cetuximab and platinum-based chemotherapy, compared with cetuximab and chemotherapy alone, as first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The management of patients with SD after first-line chemotherapy is an important issue because only a minority of patients with advanced NSCLC experience tumour shrinkage after standard platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Thus platinum-based chemotherapy combined with cetuximab represents a new treatment option for patients with advanced NSCLC and high EGFR expression in their tumors. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "More than 70% of NSCLC patients have locally advanced or metastatic disease at diagnosis, which are then being treated with platinum-based chemotherapy or epidermal-growth-factor-receptor (EGFR) inhibitors in patients harboring activating EGFR-mutations. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " INTRODUCTION: Based on the results of several randomised controlled trials, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have now replaced platinum-based chemotherapy as first-line therapy for advanced non-small cell lung cancer (NSCLC) harboring an activating EGFR mutation. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In conclusion, afatinib is an important option for the first-line treatment of patients with advanced NSCLC and activating EGFR mutations, and provides an additional option for the treatment of patients with squamous NSCLC that has progressed following first-line platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib (EGFR-tyrosine kinase inhibitor) in advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "However, the majority of patients with NSCLC will ultimately develop resistance to initial platinum-based chemotherapy, and many remain candidates for subsequent lines of therapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The present study was designed to further evaluate the efficacy and safety of icotinib in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Platinum-based chemotherapy remains as the standard of treatment for most of advanced non-small cell lung cancer (NSCLC) patients, and although therapeutic improvements have been achieved in the last years, the benefits are quite modest. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Treatments for advanced NSCLC are largely palliative and a benefit plateau appears to have reached with the platinum-based chemotherapy regimens. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " The aim of this study was to determine the response of advanced-stage non-small cell lung cancer (NSCLC) patients with or without EGFR mutations to platinum-based chemotherapy with or without gefitinib maintenance. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Treatment of unselected patients with advanced non-small cell lung cancer (NSCLC) receiving third-generation platinum-based chemotherapy has reached a plateau of effectiveness. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Clinical trials have demonstrated that the response to icotinib among advanced non-small-cell lung cancer (NSCLC) patients who received at least one platinum-based chemotherapy regimen was not inferior to gefitinib. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The objective of the current study was to evaluate the cost-effectiveness of maintenance gefitinib therapy after four chemotherapeutic cycle's stand first-line platinum-based chemotherapy for patients with locally advanced or metastatic NSCLC with unknown EGFR mutations, from a Chinese health care system perspective. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Maintenance gefitinib following first-line platinum-based chemotherapy for patients with locally advanced/metastatic NSCLC with unknown EGFR mutations is not cost-effective. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Chemotherapy with platinum agents is the standard of care for non-small-cell lung cancer (NSCLC); however, novel molecular-targeted agents like gefitinib have been approved for advanced NSCLCs, including recurrent cases previously treated with platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Erlotinib was first approved for the treatment of unselected NSCLC patients with advanced disease after failure of at least one prior chemotherapy regimen, and it was subsequently demonstrated to also confer a significant clinical benefit as maintenance therapy after first-line platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Fourteen advanced NSCLC patients showing disease progression after platinum-based chemotherapy regimens were recruited. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Phase III randomized studies have clearly demonstrated that a reversible EGFR-TKI is significantly superior in terms of response rate, progression-free survival and quality of life to platinum-based chemotherapy in advanced NSCLC patients who carry an activating EGFR mutation, thus resulting into a new standard of care for this biologically selected group of patients. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Results of the TRUST study in the Polish population confirmed the efficacy of erlotinib in advanced NSCLC after failure of prior platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The most common mutations (L858R and exon 19 deletions) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum-based chemotherapy in patients with advanced NSCLC. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Chinese female patients with locally advanced or metastatic NSCLC who failed at least one platinum-based chemotherapy received gefitinib monotherapy (250 mg/day) between April 2002 and January 2010. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: In this phase 2, multicentre, non-randomised, open-label study, we enrolled adult patients (aged \u226518 years) with pretreated metastatic stage IV BRAF(V600E)-mutant NSCLC who had documented tumour progression after at least one previous platinum-based chemotherapy and had had no more than three previous systemic anticancer therapies. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: This multicentre, open-label, randomized, controlled phase II study evaluated cilengitide in combination with cetuximab and platinum-based chemotherapy, compared with cetuximab and chemotherapy alone, as first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "EORTC 08092 evaluated pazopanib given as maintenance treatment following standard first line platinum-based chemotherapy in patients with advanced NSCLC. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Switch maintenance with pazopanib following platinum-based chemotherapy in advanced NSCLC patients had limited side-effects. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2 : 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m(2) i.v. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVES: Platinum-based chemotherapy with bevacizumab is a standard therapy for patients with stage IIIB/IV non-small cell lung cancer (NSCLC) with non-squamous (NS) histology. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Summary data from randomised trials comparing first-line bevacizumab plus platinum-based chemotherapy with chemotherapy alone for inoperable locally advanced, recurrent or metastatic NSCLC were meta-analysed. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Bevacizumab significantly prolonged OS and PFS when added to first-line platinum-based chemotherapy in patients with advanced NSCLC; no unexpected toxicity was evident. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The Keynote 024 is randomized, open-label, international, phase III study to evaluate the efficacy of pembrolizumab, an antibody directed to programmed death 1 (PD-1),an immune checkpoint inhibitor, compared with platinum-based chemotherapy in patients with previously untreated advanced NSCLC and PD-L1 expression in at least 50% of the tumour cells. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " For the majority of patients without oncogene-driven non-small cell lung cancer (NSCLC), first-line platinum-based chemotherapy represented until recently the standard treatment approach. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Expert opinion: The addition of ramucirumab to docetaxel in the treatment of patients with metastatic NSCLC who have progressed on or after platinum-based chemotherapy confers a 1.4-month improvement in overall survival, with an acceptable toxicity profile. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Methods In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Conclusions In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In patients with NSCLC harboring specific genetic alterations the anti EGFR TKIs and the ALK TKIs have improved the response rate and the quality of life compared to standard platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "However, the majority of patients with NSCLC will ultimately develop resistance to initial platinum-based chemotherapy, and many remain candidates for subsequent lines of therapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Pembrolizumab has also received breakthrough status for the treatment of EGFR mutation-negative, ALK rearrangement-negative non-small cell lung cancer (NSCLC) that has progressed on or following platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Platinum-based chemotherapy is the standard front-line treatment for patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Patients with advanced NSCLC and known KRAS mutation, treated with first-line platinum-based chemotherapy, were retrieved from hospital databases. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Therefore, we investigated whether ABCG2 haplotype-tagging SNPs (htSNPs) were associated with clinical outcomes in patients with unresectable non-small cell lung cancer (NSCLC) treated with front-line platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: We genotyped 4 ABCG2 htSNPs for 129 unresectable NSCLC cases treated with first-line platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Our data suggest ABCG2 htSNPs rs2725264 (overall group and taxane-platinum combination group) and rs4148149 (gemcitabine-platinum combination group) were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Thus, the ABCG2 htSNP rs2725264 may be independently associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: First-line platinum-based chemotherapy is currently considered the standard treatment for unresectable non-small cell lung cancer (NSCLC). ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Therefore, we evaluated the impact of ERCC2 haplotype-tagging SNPs (htSNPs) on the clinical parameters of first-line platinum-based chemotherapy in unresectable NSCLC. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: We genotyped 8 ERCC2 htSNPs for 129 unresectable NSCLC (stage IIIA, 12; stage III, 36; stage IV, 82) cases treated with first-line platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: ERCC2 htSNPs rs50872 (overall), rs238405 (taxane-platinum doublets group), and rs238416 (gemcitabine-platinum doublets group) and infection related to first-line chemotherapy were associated with OS in unresectable NSCLC patients treated with first-line platinum-based chemotherapy. ", "drug": "Platinum-based chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Patients with LA-NSCLC were randomly assigned to 60\u2009Gy or 74\u2009Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib was initially approved in Japan in 2002 for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC); however, the optimal order of conventional cytotoxic chemotherapy (carboplatin and paclitaxel) and gefitinib administration has not been determined. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "gefitinib followed by carboplatin and paclitaxel to select a candidate for further development in a phase III study of chemotherapy-na\u00efve patients with advanced or metastatic NSCLC, regardless of their EGFR mutation status. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous non-small-cell lung cancer (NSCLC) was evaluated. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: This dose-finding study evaluated lenvatinib, an oral multitargeted receptor tyrosine kinase inhibitor, in combination with carboplatin/paclitaxel in chemotherapy-na\u00efve non-small-cell lung cancer (NSCLC) patients. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: The MTD for lenvatinib with carboplatin/paclitaxel is 4\u2009mg BID in advanced NSCLC patients. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: This single-stage, open-label phase II study evaluated pulse dose imatinib and weekly paclitaxel in elderly patients with advanced NSCLC. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Because of safety findings from the Evaluation of Sorafenib, Carboplatin and Paclitaxel Efficacy in NSCLC (ESCAPE) trial, patients with squamous cell histology were withdrawn from the trial in February 2008 and excluded from analysis. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Patients receiving first-line nab-paclitaxel qw, paclitaxel qw, or paclitaxel q3w for stage IV non-small-cell lung cancer (NSCLC) were identified. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: Patients with advanced NSCLC (stage IIIB or IV) were randomized to Cisplatin-Paclitaxel (Chemotherapy group, N=112) or Cisplatin-Paclitaxel plus CADI-05 (Chemoimmunotherapy group, N=109). ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: There was no survival benefit with the addition of CADI-05 to the combination of Cisplatin-Paclitaxel in patients with advanced NSCLC; however, the squamous cell subset did demonstrate a survival advantage. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: The aim of this retrospective study was to investigate the anticancer effect and toxicity of weekly administered nab-paclitaxel as a second-line chemotherapy in elderly patients with relapsed squamous non-small-cell lung cancer (NSCLC). ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: We retrospectively reviewed the treatment of 42 elderly patients with relapsed squamous NSCLC, who received nab-paclitaxel monotherapy as a second-line treatment from January 2010 to March 2014. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Nab-paclitaxel monotherapy administered weekly at a dose of 100 mg/m(2) is shown to be an effective and safe regimen for elderly patients with relapsed squamous NSCLC, especially for patients with stage III disease or good performance status. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " The role of single-agent nab-paclitaxel in relapsed or platinum-refractory advanced non-small cell lung cancer (NSCLC) has not been well reported in Western populations. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We analyzed the records of stage IV NSCLC patients with relapsed or platinum-refractory disease treated with single-agent nab-paclitaxel at Weill Cornell Medical College between October 2008 and December 2013. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Thirty-one stage IV NSCLC patients received a median of 4 cycles (range 1-40) of nab-paclitaxel. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Single-agent nab-paclitaxel was well tolerated and demonstrated efficacy in advanced NSCLC patients with relapsed or platinum-refractory disease. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Nab-paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer (NSCLC) in patients who are not candidates for curative surgery and/or radiation therapy. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Given its efficacy and tolerability, intravenous nab-paclitaxel plus carboplatin is a valuable first-line treatment option for patients with advanced NSCLC. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced non-small cell lung cancer (NSCLC) treated primarily with carboplatin and paclitaxel. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS & METHODS: Genomic DNA samples from 90 adult male patients diagnosed with stage IIIB/IV NSCLC were genotyped for SNPs in candidate genes of relevance to platinating agents and paclitaxel and analyzed for association with survival and toxicities in univariate and multivariate models. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or meta-static nsclc. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The newer generation albumin-bound taxane, nab-paclitaxel, has also shown similar efficacy in advanced NSCLC, both as a single agent and in combination with a platinum compound. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Docetaxel and paclitaxel as single agents have also shown efficacy in the second-line setting in advanced/metastatic NSCLC. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Albumin-bound paclitaxel (Abraxane; nab\u00ae-Paclitaxel), a novel solvent-free taxane, has demonstrated higher response rates and improved tolerability when compared with solvent-based formulations in patients with advanced MBC and NSCLC. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In a subset analysis, NSCLC patients with squamous histology had a higher ORR (41%) with nab-paclitaxel than with solvent-based paclitaxel (24%; P<.001). ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Pre-treatment samples from 65 locally advanced or oligometastatic NSCLC patients, who underwent uniform induction chemotherapy with paclitaxel and platinum followed by radiochemotherapy with vinorelbine and platinum were retrospectively analysed by immunohistochemistry. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Expression of \u03b2V-tubulin was associated with treatment response and PFS following paclitaxel-based chemotherapy of locally advanced and oligometastatic NSCLC patients. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " NSCLC (non-small cell lung cancer) often exhibits resistance to paclitaxel treatment. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Identifying the elements regulating paclitaxel response will advance efforts to overcome such resistance in NSCLC therapy. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Using in vitro approaches, we demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to paclitaxel in the treatment of lung cancer. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The identification of a miR-337-3p as a modulator of cellular response to taxanes, and STAT3 and RAP1A as regulatory targets which mediate that response, defines a novel regulatory pathway modulating paclitaxel sensitivity in lung cancer cells, which may provide novel adjuvant strategies along with paclitaxel in the treatment of lung cancer and may also provide biomarkers for predicting paclitaxel response in NSCLC. ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " We assessed the prognostic and predictive value of \u03b2-tubulin III (TUBB3) expression, as determined by immunohistochemistry, in 412 non-small cell lung cancer (NSCLC) specimens from early-stage patients who received neoadjuvant chemotherapy (paclitaxel- or gemcitabine-based) in a phase III trial (IFCT-0002). ", "drug": "paclitaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: 55 patients with progressive NSCLC after platinum therapy were randomized to receive (Arm A) cetuximab, followed by pemetrexed at progression, or (Arm B) concurrent cetuximab and pemetrexed. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVES: The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)) on Day 1 (21-day cycles) plus weekly cetuximab (400 mg/m(2) loading dose, then 250 mg/m(2)) for 4-6 cycles. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Pemetrexed, cisplatin, and cetuximab appeared efficacious and tolerable in advanced nonsquamous NSCLC patients. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: To determine whether the addition of pemetrexed to gefitinib (P+G) provides clinical benefit, compared with gefitinib monotherapy, in patients with advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve for advanced NSCLC patients from China, Japan, Korea, and Taiwan (35 sites) with advanced, EGFR-mutant, NS NSCLC were randomly assigned (2:1; computer-generated, interactive voice response) to open-label pemetrexed (500 mg/m(2) on day 1 of every 21-day cycle) plus gefitinib (250 mg/d [n = 129]) or gefitinib alone (n = 66). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " To evaluate the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in advanced EGFR-mutated non-small cell lung cancer (NSCLC) patients. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Patients and methods Patients with advanced non-squamous NSCLC harboring asensitive EGFR mutation were included in this study and randomly divided into gefitinib\u00a0+\u00a0placebo group and gefitinib\u00a0+\u00a0pemetrexed group. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Pemetrexed-containing chemotherapy has shown promise in the treatment of non-small-cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "However, although adenosquamous cell lung cancer (ASCLC) is a type of NSCLC, the availability of studies investigating its response to pemetrexed-containing chemotherapy is limited. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The aim of this study was to investigate the potential of combining gefitinib and pemetrexed in preventing the acquisition of resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines harboring EGFR exon 19 deletion. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: The effect of different combinatorial schedules of gefitinib and pemetrexed on cell proliferation, cell cycle, apoptosis, and acquisition of gefitinib resistance in PC9 and HCC827 NSCLC cell lines and in PC9 xenograft models was investigated. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: The efficacy results from an open-label, randomized, multicenter study found no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) and unknown epidermal growth factor receptor (EGFR) mutation status (hazard ratio favored PC/G). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " INTRODUCTION: The primary analysis of this open-label, randomized, multicenter phase 3 study revealed no significant difference in progression-free survival between pemetrexed plus cisplatin followed by maintenance gefitinib (PC/G) and gefitinib monotherapy (G) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) and unknown epidermal growth factor receptor gene (EGFR) mutation status; however, the hazard ratio favored PC/G. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: We recently reported on a randomized, open-label, phase 3 trial comparing pemetrexed-cisplatin chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in patients with non-small cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We evaluated the efficacy and safety of a combination regimen of gefitinib and pemetrexed as first-line chemotherapy in EGFR-mutated NSCLC patients. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Considering the disease control rate and the tolerance of patients with advanced NSCLC, pemetrexed is strongly recommended to be used in clinical. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m\u00b2 of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "AP regimen (pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous non-small cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: CTONG0806 assessed the efficacy of pemetrexed versus gefitinib as second-line treatment in advanced nonsquamous nonsmall-cell lung cancer (NSCLC) harboring wild-type epidermal growth factor receptor (EGFR). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: Patients with locally advanced or metastatic nonsquamous NSCLC harboring wild-type EGFR, detected by direct sequencing, and previously treated with platinum-based chemotherapy were randomized to receive gefitinib (250 mg/day) orally or pemetrexed (500 mg/m(2)) i.v. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: CTONG0806 is the first trial to show significant improvement in PFS and an improved OS trend with pemetrexed compared with gefitinib as second-line setting treatment of EGFR wild-type advanced nonsquamous NSCLC. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In the pivotal LUX-Lung 3 study, afatinib demonstrated a prolonged progression free survival over standard pemetrexed plus cisplatin chemotherapy (11.1 versus 6.9 months; HR = 0.58, 95% CI: 0.43-0.78; P = 0.001) in EGFR mutation positive NSCLC patients. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The purpose of the present study was to investigate the combined effects of gefitinib and pemetrexed on EGFR-TKI-sensitive and EGFR\u2011TKI\u2011resistant human non-small cell lung cancer (NSCLC) cell lines. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The antiproliferative effects of gefitinib and pemetrexed, alone and in combination, on the growth of NSCLC cell lines, were assessed using an MTT assay. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In the present study, it was identified that when cells were concurrently exposed to pemetrexed and gefitinib, cytotoxic synergism was present in the gefitinib-resistant PC9/GR human NSCLC cell line and antagonistic interactions were observed in the gefitinib-sensitive PC9 cell line. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The combination of pemetrexed and gefitinib generated synergistic effects in gefitinib-acquired resistant cells and antagonistic effects in gefitinib-sensitive cells, suggesting that EGFR-TKIs combined with pemetrexed may be a beneficial treatment strategy for NSCLC patients with acquired resistance to EGFR-TKIs. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u665a\u671f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u80bf\u7624\u7ec4\u7ec7\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08epidermal growth factor recetor, EGFR\uff09\u7a81\u53d8\u662f\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08tyrosine kinase inhibitor, TKI\uff09\u6700\u91cd\u8981\u7684\u7597\u6548\u9884\u6d4b\u6307\u6807\uff0c\u4f46\u60a3\u8005\u5e38\u5e38\u56e0\u80bf\u7624\u7ec4\u7ec7\u91cf\u592a\u5c11\u5bfc\u81f4EGFR\u7a81\u53d8\u72b6\u6001\u672a\u660e\u3002TKI\u53ef\u4ee5\u8bf1\u5bfc\u80bf\u7624\u7ec6\u80de\u51cb\u4ea1\uff0c\u5e76\u4e0e\u8bb8\u591a\u51cb\u4ea1\u76f8\u5173\u57fa\u56e0\u8868\u8fbe\u76f8\u5173\u3002\u901a\u8fc7\u68c0\u6d4bGNAS1\u57fa\u56e0 T393C\u591a\u6001\u6027\uff0c\u63a2\u8ba8\u5176\u4e0eEGFR\u7a81\u53d8\u72b6\u6001\u672a\u660e\u7684\u590d\u6cbb\u665a\u671fNSCLC\u5c0f\u5206\u5b50TKI\u6cbb\u7597\u7597\u6548\u7684\u5173\u7cfb\u3002 \u65b9\u6cd5 \u5165\u7ec42009\u5e741\u67081\u65e5-2012\u5e744\u670830\u65e5\u5c31\u8bca\u4e8e\u6d59\u6c5f\u7701\u80bf\u7624\u533b\u9662\u7684116\u4f8b\u590d\u6cbb\u665a\u671fNSCLC\u60a3\u8005\uff0c\u6240\u6709\u60a3\u8005\u65e2\u5f80\u5747\u63a5\u53d7\u8fc7\u5316\u7597\uff0c\u8fdb\u5c55\u540e\u63a5\u53d7\u5409\u975e\u66ff\u5c3c\u6216\u5384\u6d1b\u66ff\u5c3c\u9776\u5411\u6cbb\u7597\u3002 \u91c7\u7528\u591a\u805a\u9176\u94fe\u53cd\u5e94\u65b9\u6cd5\u68c0\u6d4b\u60a3\u8005\u5916\u5468\u8840\u767d\u7ec6\u80de\u4e2dGNAS1\u57fa\u56e0T393C\u591a\u6001\u6027\u3002\u91c7\u7528SPSS 18.0\u7edf\u8ba1\u8f6f\u4ef6\u5206\u6790\u3002 \u7ed3\u679c \u603b\u6709\u6548\u738729.3%\uff0cGNAS1\u57fa\u56e0T393C\u5404\u57fa\u56e0\u578b\u60a3\u8005\u95f4\u7684\u6709\u6548\u7387\u65e0\u660e\u663e\u5dee\u5f02\u3002\u76f8\u6bd4GNAS1\u57fa\u56e0\u5176\u5b83\u57fa\u56e0\u578b\uff0cCC\u578b\u75be\u75c5\u63a7\u5236\u7387\u66f4\u4f4e\uff0846.2% vs 73.8%, P=0.039\uff09\u3002\u5355\u56e0\u7d20\u5206\u6790\u4e2d\u4f4dPFS\uff0cCC\u578b\u4e2d\u4f4d\u65e0\u8fdb\u5c55\u65f6\u95f4\u77ed\u4e8e\u5176\u5b83\u57fa\u56e0\u578b\uff082.3\u4e2a\u6708 vs 6.0\u4e2a\u6708\uff0cP=0.005\uff09\uff0c\u800c\u5973\u6027\u957f\u4e8e\u7537\u6027\uff0810.2\u4e2a\u6708 vs 4.6\u4e2a\u6708\uff0cP=0.04)\uff1b\u4e0d\u5438\u70df\u8005\u957f\u4e8e\u6709\u5438\u70df\u53f2\u8005\uff0811.9\u4e2a\u6708 vs 2.5\u4e2a\u6708\uff0cP<0.001)\uff1b\u75c5\u7406\u7c7b\u578b\u4e3a\u817a\u764c\u957f\u4e8e\u5176\u4ed6\u7c7b\u578b\uff0811.9\u4e2a\u6708 vs 4.1\u4e2a\u6708\uff0cP<0.001)\uff0c\u5747\u8fbe\u5230\u7edf\u8ba1\u5b66\u5dee\u5f02\u3002\u591a\u56e0\u7d20\u5206\u6790\u7ed3\u679c\u663e\u793a\uff0c\u5305\u62ec\u5438\u70df\u53f2\u3001ECOG\u8bc4\u5206\u548c\u75c5\u7406\u7c7b\u578b\u3001GNAS1\u57fa\u56e0\u591a\u6001\u6027\u4e3aPFS\u7684\u72ec\u7acb\u9884\u540e\u56e0\u7d20\uff08P=0.006 \uff09\u3002\u7ed3\u8bba \u5bf9\u590d\u6cbb\u665a\u671fEGFR\u7a81\u53d8\u72b6\u6001\u672a\u660e\u7684NSCLC\uff0cGNAS1\u57fa\u56e0T393C\u57fa\u56e0\u578b\u4e3aCC\u8005\u662f\u63d0\u793a\u8fd1\u671f\u7597\u6548\u8f83\u5dee\u7684\u6307\u6807\u3002 DOI: 10.3779/j.issn.1009-3419.2014.04.06 PMID: 24758907 [PubMed - indexed for MEDLINE]  Current pemetrexed/platinum chemotherapy does not produce a satisfactory therapeutic response in advanced lung cancer patients. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The aim of this study was to determine whether the administration of gefitinib, a tyrosine kinase inhibitor (TKI), intercalated with pemetrexed/platinum could improve the efficacy in chemotherapy-na\u00efve patients with advanced non-squamous NSCLC without subsequent gefitinib maintenance therapy. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The outstanding results of the JMEN study proved that maintenance of pemetrexed significantly improved the overall survival (OS) in advanced NSCLC patients was a proof of principle. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND AND OBJECTIVE: Gefitinib and Pemetrexed are drugs used as second-line therapy for advanced non-small cell lung cancer (NSCLC), although studies comparing the two drugs are limited. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The aim of this study is to explore the effects, safety, and quality of life (QoL) of Gefitinib and Pemetrexed on patients with advanced non-squamous NSCLC. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Forty-six advanced non-squamous NSCLC patients who failed to first-line therapy were randomly divided into two groups with 23 patients each, one using oral Gefitinib (Gefitinib group) and the other using intravenous injection Pemetrexed (Pemetrexed group). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: East Asian, never-smoker, chemo-na\u00efve patients with stage IIIB/IV NSCLC, performance status \u22641 and unknown EGFR mutation status were randomized 1:1 to receive 4 cycles of pemetrexed [500 mg/m(2)]+cisplatin [75 mg/m(2)] q3 weeks, followed by maintenance with either gefitinib [250 mg/d] (PC/G) or pemetrexed [500 mg/m(2)] q3 weeks and \u22642 optional cycles of cisplatin (PC/P). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVES: LUME-Lung 2 investigated the efficacy/safety of nintedanib plus pemetrexed in patients with pretreated non-squamous non-small cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Patients with stage IIIB/IV or recurrent non-squamous NSCLC who had received one prior chemotherapy regimen were randomized (1:1 stratified by histology [adenocarcinoma/non-adenocarcinoma], prior bevacizumab, Eastern Cooperative Oncology Group performance status and presence of brain metastases) to receive intravenous pemetrexed 500mg/m(2) on Day 1 plus nintedanib 200mg orally twice daily or matching placebo on Days 2-21, every 3 weeks until progression/unacceptable toxicity. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Although recruitment stopped prematurely, combining nintedanib with pemetrexed significantly prolonged PFS in patients with advanced non-squamous NSCLC after first-line chemotherapy, with a manageable safety profile. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " INTRODUCTION: Bevacizumab- and pemetrexed-based therapies have demonstrated activity in patients with non-small-cell lung cancer (NSCLC) and nonsquamous histologic features. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: The aim of our study was to investigate the efficacy and safety of pemetrexed monotherapy in chemo-na\u00efve Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 patients with epidermal growth factor receptor (EGFR) wild-type or unknown advanced non-squamous non-small cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Pemetrexed was administered at 500\u00a0mg/m(2) triweekly until progression with supplementations in chemo-na\u00efve ECOG PS 2 patients with EGFR wild-type or unknown advanced non-squamous NSCLC. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Pemetrexed monotherapy demonstrated moderate efficacy and good safety in chemo-na\u00efve PS 2 patients with EGFR wild-type or unknown non-squamous NSCLC. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This phase 2 study investigated ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in advanced/metastatic NSCLC. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: The primary endpoint of significant prolongation of PFS was not met; however, ramucirumab showed evidence of clinical activity in combination with pemetrexed and platinum in nonsquamous NSCLC patients. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous non-small-cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Although ORR and PFS were in accordance with most historical first-line NSCLC studies, this combination of ziv-aflibercept/cisplatin/pemetrexed will not be further explored in NSCLC. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: From August 2008 to May 2011, consecutive chemo-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) received pemetrexed 500mg/m(2), oxaliplatin 100mg/m(2) and bevacizumab 7.5mg/kg every 3 weeks for 6 cycles, in the outpatient setting. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: In this single centre experience, the combination of pemetrexed, oxaliplatin and bevacizumab was well tolerated and had promising activity as first-line therapy in unselected patients with stage IV non-squamous NSCLC. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In particular, in case of WT NSCLC with non-squamous histology, the use of platinum-based combinations including pemetrexed or bevacizumab became the standard treatment and the maintenance therapy with pemetrexed a further opportunity for selected patients. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs \u22651%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "INTERPRETATION: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: In this cohort of patients with advanced NSCLC, patients received a platinum agent with or without bevacizumab or pemetrexed, a TKI, or a single agent. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In this study, the efficacy and toxicity of the combination of irinotecan plus cisplatin (IC) was compared to pemetrexed plus cisplatin (PC) regimen, in platinum-na\u00efve patients with advanced NSCLC, who had been previously treated with the combination of a taxane plus gemcitabine. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: A total of 124 patients with locally advanced or metastatic NSCLC were randomly assigned to either irinotecan 110\u00a0mg/m(2) on day 1 and 100\u00a0mg/m(2) on day 8 plus cisplatin 80\u00a0mg/m(2) on day 8 every 3\u00a0weeks (IC arm) or pemetrexed 500\u00a0mg/m(2) plus cisplatin 80\u00a0mg/m(2) on day 1 every 3\u00a0weeks (PC arm). ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "For the 50% of patients with EGFR-mutated NSCLC who progress on EGFR-tyrosine kinase inhibitors (without evidence of a T790M mutations) as well as platinum doublets and pemetrexed/taxane, no other clinically established treatment options exist. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: Second-line chemotherapy of advanced non-small cell lung cancer (NSCLC) with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This review attempts to address three fundamental questions clinicians face in choosing first-line and maintenance treatment for advanced NSCLC, particularly nonsquamous histology: Is pemetrexed or a taxane agent better for combination with platinum therapy? Should bevacizumab be used, and is it beneficial when added to pemetrexed chemotherapy? When is maintenance therapy indicated, and which agent is best?  BACKGROUND: CHFR expression has previously been established as a powerful predictor for response to taxane based first-line chemotherapy in non-small cell lung cancer. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Pemetrexed is used for maintenance therapy for non-squamous NSCLC, whereas patients with squamous NSCLC lack easy options for maintenance therapy. ", "drug": "pemetrexed", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: The use of antiangiogenic therapy in non-small cell lung cancer (NSCLC) requires thorough evaluation of patient characteristics in order to avoid potential safety issues, particularly pulmonary haemorrhage (PH). ", "drug": "haemorrhage", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous non-small-cell lung cancer (NSCLC). ", "drug": "haemorrhage", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "METHODS: Patients with LA-NSCLC were randomly assigned to 60\u2009Gy or 74\u2009Gy radiotherapy (RT) with concurrent carboplatin/paclitaxel +/- cetuximab on NRG Oncology RTOG 0617. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: EGFR expression in diagnostic biopsies and resection specimen was compared in 53 NSCLC patients stage T1-4N0-1M0 treated with surgery without preceding chemotherapy (OP group), and 65 NSCLC patients stage T1-3N0-2M0 (NAC group) treated with preoperative carboplatin and paclitaxel in order to evaluate the discordance of EGFR expression between samples. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We designed this phase II trial to evaluate the safety, tolerability, and efficacy of the combination of carboplatin, paclitaxel, cetuximab, and bevacizumab in chemotherapy-naive patients with advanced, nonsquamous NSCLC. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " This open label, single arm phase II study was designed to evaluate the efficacy and safety of the addition of cetuximab to first line chemotherapy with carboplatin and weekly docetaxel in patients with advanced non small-cell lung cancer (NSCLC). ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "From February 2007 to December 2008 74 patients with NSCLC (stage IIIB and IV), ECOG PS \u22642 and no prior systemic chemotherapy were enrolled and treated with carboplatin (area under the curve=5 on day 1) and docetaxel (35 mg/m(2) on days 1, 8, and 15). ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Results from this phase II study suggest that the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel results in a considerable clinical efficacy with an acceptable toxicity profile for patients with advanced or metastatic NSCLC. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib was initially approved in Japan in 2002 for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC); however, the optimal order of conventional cytotoxic chemotherapy (carboplatin and paclitaxel) and gefitinib administration has not been determined. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "gefitinib followed by carboplatin and paclitaxel to select a candidate for further development in a phase III study of chemotherapy-na\u00efve patients with advanced or metastatic NSCLC, regardless of their EGFR mutation status. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This randomized phase 2 study compared the efficacy of paclitaxel and carboplatin (PC) intercalated with gefitinib (G) versus PC alone in a selected, chemotherapy-na\u00efve population of advanced NSCLC patients with a history of smoking or wild-type EGFR. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVE: Assess the cost-effectiveness of an EGFR-mutation testing strategy for advanced NSCLC in first-line therapy with either gefitinib or carboplatin-paclitaxel in Mexican institutions. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: The combination use of gefitinib and EGFR testing can be considered a cost-effective first-line therapy compared to chemotherapy such as carboplatin-paclitaxel for the treatment for NSCLC in Japan. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: Chemotherapy-na\u00efve patients with advanced non-squamous, EGFR-mutant NSCLC were randomly assigned to receive either a concurrent or a sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed [area under the curve (AUC) = 6 and 500 mg/m(2); 3-weekly]. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This was a multicentre, single-arm, phase II trial of carboplatin, S-1, and gefitinib in advanced NSCLC patients with activating EGFR mutations. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Combination chemotherapy with carboplatin, S-1, and gefitinib is efficacious and well tolerated as a first-line treatment in advanced NSCLC patients with activating EGFR mutations. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Treatment-na\u00efve patients with stage IIIB or IV NSCLC were randomly assigned to receive pemetrexed (500 mg/m (2) d1) and either cisplatin (75 mg/m (2) d1) or carboplatin (AUC = 5 d1) plus gefitinib (250 mg/d on days 3 to 16 of a 3-week cycle) (PC-G) or pemetrexed-platinum (PC) alone. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: In this open-label, phase II study, patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations (either exon 19 deletion or L858R point mutation) were assigned randomly to receive pemetrexed (500\u00a0mg/m(2)) and carboplatin (AUC\u00a0=\u00a05), administered every 21\u00a0days for 4 cycles, followed with or without gefitinib (250\u00a0mg/day) for 6\u00a0months. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel (PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation, previously reported superiority of gefitinib over CBDCA/PTX on progression-free survival (PFS). ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Therefore, this analysis evaluates the Quality Adjusted progression free survival of gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin (Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV NSCLC. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: For non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, first-line gefitinib produced a longer progression-free survival interval than first-line carboplatin plus paclitaxel but did not show any survival advantage in the North East Japan 002 study. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Chemotherapy-na\u00efve patients with sensitive EGFR-mutated, advanced NSCLC were randomized to receive gefitinib or chemotherapy (carboplatin and paclitaxel). ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVE: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-na\u00efve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Chemotherapy-na\u00efve patients with non-squamous NSCLC were randomly assigned to maintenance therapy with pemetrexed and bevacizumab or pemetrexed alone, after achieving disease control after four cycles of induction therapy with carboplatin (area under the curve = 6), pemetrexed (500 mg/m(2)), and bevacizumab (15 mg/kg). ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Both maintenance therapy with pemetrexed alone and pemetrexed and bevacizumab in combination were feasible in patients with non-squamous NSCLC who have achieved disease control after induction therapy with carboplatin, pemetrexed, and bevacizumab. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " AIM: The present study aimed to evaluate the effectiveness and safety of weekly paclitaxel (PTX) combined with carboplatin (CBDCA) plus bevacizumab (BEV), followed by maintenance BEV in patients with advanced NSCLC. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "On the basis of these factors, a treatment algorithm for clinical practice to categorize unfit NSCLC patient into 3 major clinical scenarios was defined: (1) unfit for cisplatin-based chemotherapy, (2) unfit for carboplatin-based chemotherapy, and (3) unfit for single-agent chemotherapy. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Eligible stage IV nonsquamous NSCLC patients with no prior chemotherapy for metastatic disease were randomized 1:1 to pemetrexed and carboplatin (or cisplatin) or ramucirumab (10 mg/kg) plus pemetrexed and carboplatin (or cisplatin) once every 3 weeks. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Efficacy and safety of first-line axitinib/paclitaxel/carboplatin versus bevacizumab/paclitaxel/carboplatin in advanced non-squamous non-small-cell lung cancer (NSCLC) was evaluated. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: In patients with advanced non-squamous NSCLC, axitinib/paclitaxel/carboplatin did not improve efficacy versus bevacizumab/paclitaxel/carboplatin, and was less well tolerated. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: This dose-finding study evaluated lenvatinib, an oral multitargeted receptor tyrosine kinase inhibitor, in combination with carboplatin/paclitaxel in chemotherapy-na\u00efve non-small-cell lung cancer (NSCLC) patients. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: The MTD for lenvatinib with carboplatin/paclitaxel is 4\u2009mg BID in advanced NSCLC patients. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: This study was initiated to assess the safety and efficacy of biweekly carboplatin and gemcitabine with bevacizumab in treatment-naive patients with advanced and metastatic non-small cell lung cancer (NSCLC). ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Biweekly therapy with combination of carboplatin, gemcitabine, and bevacizumab in advanced inoperable NSCLC provided limited benefit and was associated with excessive toxicity. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Because of safety findings from the Evaluation of Sorafenib, Carboplatin and Paclitaxel Efficacy in NSCLC (ESCAPE) trial, patients with squamous cell histology were withdrawn from the trial in February 2008 and excluded from analysis. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Patients with chemotherapy-naive, stage IIIB or IV, non-squamous NSCLC without targetable EGFR or ALK genetic aberrations were randomly assigned (1:1) in blocks of four stratified by PD-L1 tumour proportion score (<1% vs \u22651%) using an interactive voice-response system to 4 cycles of pembrolizumab 200 mg plus carboplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maintenance therapy. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "INTERPRETATION: Combination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-line treatment option for patients with advanced non-squamous NSCLC. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Nab-paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer (NSCLC) in patients who are not candidates for curative surgery and/or radiation therapy. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Compared with sb-paclitaxel plus carboplatin, nab-paclitaxel plus carboplatin significantly improved the objective response rate (ORR), but did not prolong progression-free survival or overall survival (OS), in the overall population of patients with advanced NSCLC in a multinational phase III trial. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Given its efficacy and tolerability, intravenous nab-paclitaxel plus carboplatin is a valuable first-line treatment option for patients with advanced NSCLC. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The present study aimed to identify pharmacogenetic markers associated with clinical response and toxicity in patients with advanced non-small cell lung cancer (NSCLC) treated primarily with carboplatin and paclitaxel. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or meta-static nsclc. ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "A recent phase III trial in NSCLC compared nab-paclitaxel with carboplatin versus solvent-based paclitaxel with carboplatin, and found improved overall response rates (ORRs) in the nab-paclitaxel arm (33% vs 25%; P=.005). ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: We have reported promising results of surgery after induction chemoradiotherapy (carboplatin-taxane, 50 Gy radiation) for cN2,3 non-small cell lung cancer (NSCLC). ", "drug": "carboplatin", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "AUTHORS' CONCLUSIONS: Erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased tumour response rate and prolonged progression-free survival compared to cytotoxic chemotherapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Moreover, the novel combination of bevacizumab and erlotinib is very promising for the treatment of patients with NSCLC harbouring EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in Non-Small Cell Lung Cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "By screening 40 non-small cell lung cancer cell (NSCLC) lines, we established a surprising positive correlation between the presence of a KRAS mutation and radiosensitization by the EGFR inhibitors erlotinib and cetuximab. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " INTRODUCTION: The phase III SATURN study demonstrated that first-line maintenance erlotinib extended progression-free survival (PFS) and overall survival (OS) versus placebo in patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: These data suggest that EGFR IHC does not have value as a marker to predict erlotinib benefit in the first-line maintenance setting for advanced NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: We reviewed the electronic records of patients with NSCLC treated with an EGFR inhibitor-based combination regimen: erlotinib and cetuximab; erlotinib, cetuximab and bevacizumab; erlotinib and dasatinib; erlotinib and bortezomib; or cetuximab and sirolimus. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Eight of 34 evaluable patients (24%) with advanced, refractory NSCLC evaluable for response achieved SD \u22656 months/PR (PR=3; SD \u22656 months=5) on EGFR inhibitor-based combination regimens (erlotinib, cetuximab; erlotinib, cetuximab and bevacizumab; and, erlotinib, bortezomib), including patients with secondary resistance to single-agent EGFR inhibitors, resistant mutations, wild-type disease, and, squamous histology. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non-small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: The combination of erlotinib, cetuximab, and bevacizumab was well-tolerated and demonstrated antitumor activity in heavily pretreated patients with NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "First, the effects of tyrosine kinase inhibitors (erlotinib hydrochloride, sorafenib tosilate and sunitinib malate) against human non-small cell lung cancer (NSCLC), breast cancer and colorectal cancer were evaluated in vivo. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "S-1 and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, showed a significant inhibition of growth in human NSCLC (Lu-99 and PC-9 cell lines). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In this study, we investigated the effects of the combination of Erlotinib and Cetuximab on T790M and L858R mutation lung cancer cells lines (H1975), in the primary NSCLC cells with the T790M mutation and TKI-resistant EGFR mutations human tumor xenograft model (H1975). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "RESULTS: Compared with single-agent treatment, the combination of Cetuximab and Erlotinib increased apoptosis of EGFR TKI-resistant NSCLC cells (H1975), resulting in more pronounced growth inhibition on cell proliferation and significant inhibition of EGFR-dependent signaling. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "To identify genes that are specifically methylated during the evolution of resistance to anti-EGFR therapeutic agents, we performed a methylation-specific array containing a panel of 56 genes that are commonly known to be regulated through promoter methylation in two parental non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) cell lines and their resistant derivatives to either erlotinib or cetuximab. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Restoration of DAPK into the resistant NSCLC cells by stable transfection re-sensitized the cells to both erlotinib and cetuximab. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " The introduction of first- and second-generation EGFR-tyrosine kinase inhibitors (TKIs) (gefitinib, erlotinib and afatinib) for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC) has dramatically improved patients' prognosis and quality of life (QoL). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "As a result, EGFR TKI therapy, including gefitinib, erlotinib and afatinib, has become the standard therapy for NSCLC patients with EGFR activating mutation as first-line therapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Currently, the first-generation gefitinib and erlotinib and second-generation afatinib have been approved for first-line treatment of metastatic NSCLC with activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Targeted therapies directed against epidermal growth factor receptor (EGFR), such as gefitinib, erlotinib and afatinib, achieved important improvements in EGFR mutated NSCLC with favorable toxicity profile. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Three EGFR-TKIs, namely afatinib, erlotinib and gefitinib, are currently available for the treatment of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: The records of NSCLC patients harboring EGFR mutations who were treated with gefitinib or erlotinib were retrospectively reviewed, and the treatment outcomes were evaluated. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Another trial is now investigating the bene\ufb01cial effects of curcumin plus gefitinib or erlotinib for EGFR-mutant NSCLC, although this trial is ongoing. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: The subjects studied were 74 NSCLC patients with common EGFR mutations treated with gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as Gefitinib and Erlotinib, are effective clinical medicines for advanced NSCLC patients harboring EGFR-activating mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " INTRODUCTION: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced EGFR-mutated NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We retrospectively reviewed 922 consecutive patients with EGFR-mutant non-small cell lung cancer (NSCLC) patients administered with gefitinib/erlotinib at Guangdong General Hospital. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: The BIM deletion polymorphism is associated with apoptosis resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, in non-small cell lung cancer (NSCLC) harboring EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in non-small cell lung cancer (NSCLC) patients for the prevention and treatment of erlotinib-induced gastrointestinal injury and corticosteroid-associated gastric irritation. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: A retrospective database analysis of 157 patients given erlotinib or gefitinib for EGFR-mutant advanced NSCLC from two institutions was conducted. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The epidermal growth factor receptor (EGFR) mutant NSCLCs frequently respond to the EGFR tyrosine kinase inhibitors (EGFR-TKIs) treatment, such as Gefitinib and Erlotinib, but the development of acquired resistance limits the utility. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In the second-line treatment of advanced squamous non-small cell lung cancer (NSCLC), afatinib significantly prolonged PFS and OS, compared with erlotinib, regardless of EGFR mutation status (LUX-Lung 8 trial). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This study evaluated the efficacy and safety of a c-Met selective inhibitor, tivantinib (ARQ 197), in combination with erlotinib, in Japanese EGFR mutation-positive patients with NSCLC who progressed while on EGFR-TKIs. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: This study enrolled 45 patients with NSCLC with acquired resistance to EGFR-TKIs, who were orally administered a daily combination of tivantinib/erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: The objective of the study was to observe the efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib in patients with advanced non-small cell lung cancer (NSCLC) with secondary drug resistance to standard doses of tyrosine kinase inhibitor (TKI) treatment. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: We recruited 42 NSCLC patients from our hospital, between August 2014 and December 2015, who had experienced drug resistance after one year of conventional treatment with gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Patients with advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) are particularly sensitive to treatment with first- or second-generation EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib and afatinib, which block the cell-signaling pathways that drive the growth of tumor cells. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MEDLINE, PubMed, Cochrane, and Google Scholar databases were searched until October 21, 2015 using the following search terms: lung neoplasms/lung cancer/non-small cell lung cancer/NSCLC, EGFR, gene amplification, copy number, erlotinib, gefitinib, tyrosine-kinase inhibitor/TKI, predictor. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: The emergence of EGFR inhibitors such as gefitinib, erlotinib, and osimertinib has provided novel treatment opportunities in EGFR-driven non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Currently, the first-generation EGFR/HER-TKIs gefitinib and erlotinib and second-generation EGFR/HER-TKI afatinib have been approved for use as the first-line treatment of metastatic NSCLC with actEGFRm. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: This study was a pre-planned exploratory analysis of a randomized phase III trial conducted from 2009 to 2014 comparing erlotinib with gefitinib in advanced NSCLC harboring EGFR mutations in tumor (CTONG0901). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: The analysis included fifty two NSCLC patients treated with EGFR tyrosine kinase inhibitors (TKIs): erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, are one of the representatives of targeted therapy which have been widely used in first line, maintenance and 2nd/3rd line therapy among advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In this study, we utilized Dichloroacetate (DCA), a widely regarded PDK inhibitor, together with Erlotinib and Gefitinib, two well-known EGFR inhibitors, and demonstrated that the applications of DCA in combination with either Erlotinib or Gefitinib significantly attenuated the viability of EGFR mutant NSCLC cells (NCI-H1975 and NCI-H1650) in a synergistic manner. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "One of the potential strategies for treating acquired resistance in NSCLC is the readministration of EGFR-TKIs, a strategy that has mainly been evaluated using gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Afatinib, together with gefitinib and erlotinib, is approved for first-line treatment of advanced non-small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, have greatly improved treatment efficacy in non-small cell lung cancer (NSCLC) patients with drug-sensitive EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Three different tyrosine kinase inhibitors (TKIs) are recommended as first-line treatment of EGFR mutation-positive NSCLC: gefitinib, erlotinib, and afatinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "AUTHORS' CONCLUSIONS: Erlotinib, gefitinib, and afatinib are all active agents in EGFR M+ NSCLC patients, and demonstrate an increased tumour response rate and prolonged progression-free survival compared to cytotoxic chemotherapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Cytotoxic chemotherapy is less effective in EGFR M+ NSCLC than erlotinib, gefitinib, or afatinib and is associated with greater toxicity. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: The bevacizumab plus erlotinib study (BEVERLY) is a randomized, open-label, phase III trial investigating first-line erlotinib plus bevacizumab versus erlotinib in patients with advanced NSCLC harboring activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: If the primary endpoint of PFS is met, the erlotinib plus bevacizumab combination will be confirmed as the best first-line treatment for patients with advanced NSCLC harboring activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Here we report two cases of gefitinib- or erlotinib-pretreated NSCLCs with a T790M mutation-positive (as assessed on plasma through the therascreen EGFR test) disease and untreated, asymptomatic central nervous system metastases that responded to treatment with osimertinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Gefitinib and erlotinib target the ATP cleft in the tyrosine kinase EGFR, which is overexpressed in 40-80 percent of non-small-cell lung cancer (NSCLC) and many other epithelial cancers. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Our study indicates that AS treatment may not compromise TKI efficacy (gefitinib or erlotinib) in NSCLC patients with mutated EGFR. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Nowadays, we dispose of three different EGFR TKIs (afatinib, erlotinib and gefitinib) approved for the treatment for first-line treatment of patients di NSCLC carrying EGFR, that was compared only by indirect analysis, producing data not always clear and convincing. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Gefitinib and/or erlotinib-induced hepatotoxicity sometimes lead to treatment failure in EGFR mutation-positive patients with non-small cell lung cancer (NSCLC), even though the therapeutic effect is evident. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CASES: Here, we report three postoperative NSCLC patients with recurrences who experienced severe hepatotoxicity while receiving gefitinib and/or erlotinib treatment but could be safely switched to afatinib treatment. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced non-small cell lung cancer (NSCLC) patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: To comprehensively assess the efficacy and safety of whole-brain radiotherapy (WBRT) combined with gefitinib/erlotinib for treatment of brain metastases (BM) from non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Studies on randomized controlled trials (RCTs) and case-control trials comparing WBRT combined with gefitinib/erlotinib versus WBRT alone for BM from NSCLC were included. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: WBRT plus gefitinib/erlotinib was superior to WBRT alone and well tolerated in patients with BM from NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We recruited 226 Chinese advanced NSCLC patients who received TKIs erlotinib, gefitinib and icotinib hydrochloride and systematically studied the genetic factors associated with therapeutic responses and ADRs. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: From 2008 to 2011, 130 consecutive patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations were treated with either erlotinib or gefitinib at our institution. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Concurrent use of AS did not affect the efficacy or toxicity of erlotinib and gefitinib in patients with advanced NSCLC harboring EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, is a critical issue for the treatment of EGFR mutant-positive non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Afatinib is a second-generation epidermal growth factor receptor (EGFR) inhibitor that has been shown to be effective against EGFR-mutated non-small cell lung cancer (NSCLC) resistant to conventional EGFR inhibitors such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIAL AND METHODS: We retrospectively analyzed all NSCLC patients with EGFR-TKI (gefitinib or erlotinib) treatment at our institution between 2011 and 2013 who progressed after at least stable disease on erlotinib or gefitinib for more than 6 months. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In elderly patients with advanced epidermal growth factor receptor mutation-positive NSCLC, erlotinib and gefitinib appear to repeat the same favorable performance as that documented on a larger scale in the overall population of patients with activating mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations initially respond well to the EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Non-small-cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation is resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib, but responds to the ALK-TKI crizotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " RATIONALE AND OBJECTIVES: The aims of this study were to investigate the association between 8-week tumor volume decrease and survival in an independent cohort of epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first-line erlotinib or gefitinib, and to assess the rate of their volumetric tumor growth after the volume nadir. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: In patients with advanced NSCLC harboring sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, computed tomography (CT) tumor volumes of dominant lung lesions were analyzed for (1) the association with survival, and (2) the volumetric tumor growth rate after the volume nadir. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: The 8-week tumor volume decrease was validated as a marker for longer survival in the independent cohort of EGFR-mutant NSCLC patients treated with first-line erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Three EGFR inhibitors (erlotinib, gefitinib and afatinib) received a European marketing authorization for up to first line treatment of EGFR mutated NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: We retrospectively analyzed 151 patients who had NSCLC harboring EGFR mutations and had received either gefitinib or erlotinib as first-line treatment between 2005 and 2014. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: In this phase Ib/II study, we aimed to assess the safety and efficacy of afatinib plus nimotuzumab (N) in advanced non-small cell lung cancer (NSCLC) patients with acquired resistance to gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Combination treatment of afatinib and nimotuzumab demonstrated an acceptable safety profile and encouraging antitumor activity in advanced NSCLC patients with acquired resistance to gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to small molecule tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: From 2008 to 2012, 160 consecutive patients with advanced NSCLC harboring an EGFR mutation were treated with EGFR-TKIs (erlotinib or gefitinib). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Both afatinib and erlotinib are tyrosine kinase inhibitors that inhibit aberrant epidermal growth factor receptor (EGFR) signals in non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Although afatinib has been shown to be effective in the treatment for erlotinib-refractory and/or gefitinib-refractory central nervous system metastases from NSCLC, little is known about the efficacy of erlotinib for afatinib-refractory central nervous system metastases. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Our report highlights the potential benefit of erlotinib for the management of brain metastases refractory over afatinib in patients with NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " WHAT IS KNOWN AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib or gefitinib are indicated for the treatment of non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We performed a systematic review and meta-analysis to summarize the evidence regarding the association of smoking status with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Eligible studies included those evaluating the association of smoking status with OS and PFS in patients with NSCLC receiving erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "WHAT IS NEW AND CONCLUSION: Among patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib, never smokers appear to show longer OS and PFS as compared to former or current smokers. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The EGFR-TKIs gefitinib, erlotinib, and afatinib have been approved for the treatment of advanced NSCLC, and sensitivity to these drugs has been shown to be associated with the presence of EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " This meta-analysis has been conducted to determine the risk of elevated transaminases associated with the use of erlotinib, gefitinib and afatinib in patients with non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Forty-five patients with NSCLC who were treated with erlotinib following gefitinib failure at Seoul National University Hospital between August 2005 and November 2011 were enrolled. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The epidermal growth factor receptor (EGFR) inhibitors, gefitinib, erlotinib and afatinib; the anaplastic lymphoma kinase (ALK) inhibitor, crizotinib; and the anti-vascular endothelial growth factor receptor monoclonal antibody, bevacizumab, are already providing improved survival for patients with NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Given the rapid development of third-generation EGFR TKIs and the approval of gefitinib, erlotinib, and afatinib as first-line treatment of EGFR-mutant NSCLC patients, the future role of dacomitinib in the treatment of NSCLC seems to be limited. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "gefitinib, erlotinib, afatinib) in patients with NSCLC harboring EGFR mutations reach 60-80%, with a complete response rate as high as 40%. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Applying a focused shRNA screening approach to identify genes whose knockdown can prevent and/or overcome acquired resistance to erlotinib in several EGFR-mutant non-small cell lung cancer (NSCLC) cell lines, we identified casein kinase 1 \u03b1 (CSNK1A1, CK1\u03b1). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We experienced two cases of NSCLC patients who developed erlotinib-induced eyelid erosion and were then successfully treated with gefitinib, without recurrence of toxicity or disease progression. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Non-small-cell lung cancer (NSCLC) patients whose tumors have an EGFR-activating mutation develop acquired resistance after a median of 9-11 months from the beginning of treatment with erlotinib, gefitinib and afatinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " In non-small-cell lung cancer (NSCLC) patients, the activation of alternative pathways contributes to the limited efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The present study examines a panel of EGFR wild-type, K-Ras mutated, NSCLC lines, which were all intrinsically resistant to EGFR-TKIs, and demonstrates that the histone deacetylase inhibitor vorinostat can improve the therapeutic efficacy of gefitinib or erlotinib, inducing strong synergistic antiproliferative and pro-apoptotic effects that are paralleled by reactive oxygen species accumulation and by increased DNA damage. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in Non-Small Cell Lung Cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib had undergone turbulent clinical development until it was discovered that these agents have preferential activity in patients with NSCLC harboring activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The aim of this paper is to provide a comprehensive review of the major progresses reported so far in the EGFR inhibition in this molecularly-selected subgroup of NSCLC patients, from the early successes with first generation EGFR TKIs, Erlotinib and Gefitinib, to the novel irreversible and mutant-selective inhibitors and ultimately the emerging challenges that we, in the next future, are called to deal with. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Activating EGFR mutations discovery and efficacy of 1st generation tyrosine kinase inhibitors (TKI), such as erlotinib or gefitinib, inaugurated the beginning of personalized medicine in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Low-dose erlotinib may be as effective as gefitinib or erlotinib at full dose in non-small cell lung cancer (NSCLC) patients with activating mutations of the epidermal growth factor receptor (EGFR) gene. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Patients with chemotherapy pretreated NSCLC harbouring EGFR mutations received erlotinib at 50 mg/d until disease progression or unacceptable toxicities. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: The primary end-point was not met; low-dose erlotinib is not recommended for fit patients with NSCLC harbouring EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVE: To evaluate the efficacy of whole brain radiotherapy (WBRT) or/and stereotactic radiotherapy (SRT) concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors (TKI), like erlotinib and gefitinib, in the treatment of brain metastases from non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In EGFR unknown patients, nine trials (INTEREST, IRESSA as Second-line Therapy in Advanced NSCLC - KoreA, Li, Second-line Indication of Gefitinib in NSCLC, V-15-32, ISEL, DELTA, TITAN and BR.21) reported overall survival data and only one (BR.21) reported a statistically significant result favouring the use of erlotinib over BSC (HR 0.7, 95% CI 0.58 to 0.85). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Treatment with first-generation EGFR-TKIs, in particular erlotinib, may be considered a first- or second-line option for patients with NSCLC with minor EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " RATIONALE, AIMS AND OBJECTIVES: Molecular targeted drugs (MTD), gefitinib and erlotinib, have been proven to provide clinical benefits to advanced stage non-small cell lung cancer (NSCLC) patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Recently, erlotinib, a tyrosine kinase inhibitor (tki) targeting EGFR mutation, was approved as second-line treatment in EGFR wild-type nsclc. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR TKIs), such as erlotinib and gefitinib, have demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harbouring activating mutations in the EGFR gene (EGFR(mut+)). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In the present review we analysed the available data on erlotinib in the treatment of advanced NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor (EGFR) mutation have benefited from treatment of reversible EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Multiple mutations in the EGFR gene are a major cause for the failure of Erlotinib and Gefitinib in the treatment of patients harboring non-small-cell lung cancer (NSCLC) who initially responded to this therapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " All patients with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC) treated with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) such as gefitinib, erlotinib or afatinib will progress after a median of 9-12 months. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Furthermore, heregulin overexpression induced EGFR TKI resistance in NSCLC cells harbouring an activating EGFR mutation, while HER3 and AKT activation was maintained in the presence of erlotinib in heregulin-overexpressing, EGFR-mutant NSCLC cells. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Activating mutations in exons 19 or 21 of EGFR in NSCLC are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Patients with NSCLC who harbor an activating EGFR mutation show a more favorable response to treatment with an EGFR inhibitor, such as gefitinib, erlotinib, or afatinib, than to chemotherapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This study evaluated the safety, tolerability, pharmacokinetics and efficacy of patritumab (U3-1287), a fully human anti-HER3 monoclonal antibody, in combination with erlotinib, an epidermal growth factor receptor-tyrosine kinase inhibitor in patients with previously treated advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: This study enrolled patients with stage IIIB/IV NSCLC with Eastern Cooperative Oncology Group performance status 0-1, life expectancy >3 months and who had progressed after at least one prior course of chemotherapy (excluding erlotinib). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Therapeutic approach by treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib or erlotinib to non-small cell lung cancer (NSCLC) patients has been limited due to emergence of acquired drug resistance. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVE: To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Fifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " We performed a meta-analysis of fatal pulmonary events associated with erlotinib, gefitinib or afatinib in patients with non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Our meta-analysis has demonstrated that erlotinib, gefitinib and afatinib are associated with an increased risk of high-grade interstitial lung disease in patients with NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We analyzed data from 21 NSCLC patients aged \u2265 80 years who were administered gefitinib and/or erlotinib between January, 2009 and December, 2014. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Erlotinib and afatinib are similar compounds approved for the treatment of metastatic NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The objective of this study was to compare the efficacy and toxicity of erlotinib, gefitinib, and afatinib in NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Gefitinib has similar activity and toxicity compared with erlotinib and offers a valuable alternative to patients with NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVES: Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) - afatinib, erlotinib, and gefitinib - are available for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: We performed a pooled analysis of severe AEs according to the type of EGFR-TKI administered with the use of data extracted from prospective clinical trials that evaluated the clinical efficacy of gefitinib, erlotinib, or afatinib in NSCLC patients with EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Eight patients diagnosed with non-small cell lung cancer (NSCLC) (three men and five women with an average age of 69.3 years) who were initiated on treatment with EGFR inhibitors (either gefitinib [Iressa(\u00ae)] or erlotinib [Tarceva(\u00ae)]) were enrolled. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Mutations in the epidermal growth factor receptor (EGFR) gene are associated with a favorable clinical response to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib in non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The FDA-approved small-molecule inhibitors of EGFR, gefitinib (Iressa) and erlotinib (Tarceva), are clinically effective in a subset of patients with non-small cell lung cancer (NSCLC) whose tumors harbor activating mutations within the kinase domain of EGFR. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, have demonstrated marked clinical activity against non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We report data from a phase I/II, multicenter, open-label study of Korean patients with refractory KRAS wild-type adenocarcinoma NSCLC (defined as patients with evidence of disease progression during or within 6 months of treatment with chemotherapy and gefitinib or erlotinib). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "FINDINGS: New targeted therapies for molecularly selected NSCLC are changing the natural history of the disease, with results superior to standard chemotherapy as demonstrated in large phase III studies with first generation EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Erlotinib and gefitinib are among the most widely researched, used and available molecularly targeted therapies for treatment of advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In the past decade, there have been reports on clinical benefit from use of erlotinib after gefitinib failure in NSCLC patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "P7170 at a well-tolerated daily dose of 20 mg/kg significantly inhibited the growth of NSCLC xenografts independent of different mutations (EGFR, KRAS, or PIK3CA) or sensitivity to erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Our results provide evidence of antitumor activity of P7170 in the erlotinib -sensitive and -insensitive models of NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: To evaluate the efficacy and safety of alternating gefitinib and erlotinib, tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), with chemotherapy in non-small-cell lung cancer (NSCLC) patients with acquired TKI resistance. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " The epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib are effective in the treatment of advanced non-small-cell lung cancer (NSCLC), but the median survival of patients is short. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Here, we describe 2 patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Gefitinib, erlotinib, and conventional chemotherapy can be combined for satisfactory therapy for NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Other studies indicated that afatinib may offer advantages over standard chemotherapy for NSCLC in terms of enhanced symptom control and quality of life and is modestly effective in cases involving EGFRT790M-related acquired resistance to the TKIs erlotinib and gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib and erlotinib, have proven to be highly effective agents for advanced non-small cell lung cancer (NSCLC) in patients harboring an activating EGFR mutation such as the exon 19 deletion mutation and L858R. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "NSCLC patients at advanced stage (N=150) who received EGFR-TKIs (gefitinib or erlotinib) as second- or third-line therapy from September 2008 to December 2012 were included in the study. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "However, it's still too early to celebrate since the first-generation EGFR-TKIs such as gefitinib and erlotinib have only achieved limited clinical benefits and acquired resistance to this kind of drugs occurred inevitably in almost all the NSCLC patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The association of CFE, smoking history, occupational hazard exposure, tumor pathological type, EGFR mutation status, environmental exposure, living environment, and performance status with EGFR-TKI efficacy was determined in metastatic NSCLC patients who were treated with EGFR-TKIs (gefitinib or erlotinib). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The aforementioned EGFR mutations are stout predictors of response and augmentation of progression-free survival when gefitinib, erlotinib, and afatinib are used for patients with advanced NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " AIM: To evaluate the tolerability and efficacy of erlotinib treatment in advanced non-small cell lung cancer (NSCLC) patients who had previously experienced severe hepatotoxicity after gefitinib treatment. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Erlotinib treatment was efficient and well-tolerated in NSCLC patients with EGFR mutation, despite their severe hepatotoxicity with prior gefitinib treatment. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: In a total of 163 patients with advanced-stage (IIIB or IV) NSCLC treated with EGFR-TKIs (erlotinib or gefitinib), pre-treatment levels of NSE and TK were measured. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "When an EGFR mutation is found, gefitinib and erlotinib have been shown to have significant roles in the treatment of untreated advanced NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In contrast, erlotinib is potentially effective for the treatment of EGFR wild-type NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Similar to gefitinib, erlotinib is also effective for EGFR-mutated NSCLC and has been used as an initial treatment for patients with advanced EGFR-mutated NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The results of this updated pooled analysis suggest a substantial clear PFS benefit of treating patients with EGFR mutation-positive NSCLC with erlotinib or gefitinib compared with chemotherapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity, such as erlotinib and gefitinib, revolutionized therapy for non-small cell lung cancer (NSCLC) patients whose tumors harbor activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "However, many unanswered questions about the optimal use of TKIs in lung cancer remain; in particular, an open question is which of the currently available TKIs (gefitinib, erlotinib and afatinib) might be the best choice in untreated NSCLC patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: For the 2010-2013 period, the authors evaluated 158 patients diagnosed with advanced or metastatic NSCLC treated in first-, second-, or third-line with the EGFR-TKIs afatinib, erlotinib, or gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Two reversible EGFR TKIs (gefitinib, erlotinib) and the irreversible ErbB family blocker afatinib are currently approved for treatment of EGFR mutation-positive NSCLC, but no head-to-head trials have been reported to date. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Gefitinib and erlotinib are first-generation EGFR-tyrosine kinase inhibitors(EGFR-TKIs)that play a key role in activating EGFR-mutated NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " The majority of non-small cell lung cancer (NSCLC) patients harbor EGFR-activating mutations that can be therapeutically targeted by EGFR tyrosine kinase inhibitors (EGFR-TKI), such as erlotinib and gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Here, we have demonstrated that overexpression of CRIPTO1, an EGF-CFC protein family member, renders EGFR-TKI-sensitive and EGFR-mutated NSCLC cells resistant to erlotinib in culture and in murine xenograft models. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Primary NSCLC cells derived from a patient with EGFR-mutated NSCLC that was intrinsically erlotinib resistant were CRIPTO1 positive, but gained erlotinib sensitivity upon loss of CRIPTO1 expression during culture. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CRIPTO1-induced erlotinib resistance was directly mediated through SRC but not ZEB1; therefore, cotargeting EGFR and SRC synergistically attenuated growth of erlotinib-resistant, CRIPTO1-positive, EGFR-mutated NSCLC cells in vitro and in vivo, suggesting that this combination may overcome intrinsic EGFR-inhibitor resistance in patients with CRIPTO1-positive, EGFR-mutated NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib are the standard-of-care for patients with advanced NSCLC harbouring activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and L858R substitutions) are the most robust predictive biomarker for symptom improvement, radiographic response, and increment in progression-free survival (PFS) when EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: The combination of radiotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) has not been widely investigated. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but what it is still unclear is the efficacy of (EFGR-TKIs: gefitinib or erlotinib) monotherapy in previously treated non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " The first targeted agents approved for non-small cell lung cancer (NSCLC) treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "To clarify the role of EMT phenotype as a predictive marker for EGFR-TKI, we performed a retrospective study in 202 stage IV or recurrent NSCLC patients receiving gefitinib or erlotinib therapy from June 2008 to September 2012 in our institute. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Gefitinib anderlotinib, which are epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs), have been usedfor the treatment of inoperable andrecurrent non-small cell lung cancer(NSCLC)patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We compared the clinical outcomes in gefitinib- and erlotinib-treated patients harboring EGFR mutations who had recurrent or metastatic non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: A total of 375 patients with recurrent or metastatic stage IIIB/IV NSCLC, who had either exon 19 deletion or the L858R mutation in exon 21, and had received either gefitinib (n = 228) or erlotinib (n = 147), were included in the study. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: In NSCLC patients harboring EGFR mutation, treatment with gefitinib and erlotinib resulted in similar effectiveness. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " INTRODUCTION: Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Gefitinib and erlotinib are used to treat advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " The identification of activating EGFR gene mutations and the availability of effective target therapies such as gefitinib and erlotinib have radically changed the therapeutic approach and prognosis for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: A total of 148 patients who had metastatic or recurrent NSCLC with activating EGFR mutation treated with either erlotinib or gefitinib as a first-line (n = 10) and a second-line or more treatment (n = 138) were retrospectively reviewed. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Epidermal growth factor receptor (EGFR) somatic mutations are found in the majority of non-small-cell lung cancers (NSCLCs) and patients with NSCLC who harbor EGFR mutations have been shown to exhibit increased sensitivity to the small-molecule EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Afatinib showed some activity in NSCLC with acquired resistance to EGFR TKIs, although, currently, its efficacy after the failure of erlotinib or gefitinib has not been clearly stated. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib [1,2] has achieved 8-14 months of progression free survival in advanced non-small cell lung cancer (NSCLC) patient with EGFR mutation. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Inhibition of EGFR by tyrosine kinase inhibitors such as gefitinib and erlotinib has provided a new hope for the cure of NSCLC patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "However, acquired resistance to gefitinib and erlotinib via EGFR-mutant NSCLC has occurred through various molecular mechanisms such as T790M secondary mutation, MET amplification, hepatocyte growth factor (HGF) overexpression, PTEN downregulation, epithelial-mesenchymal transition (EMT), and other mechanisms. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Although non-small cell lung cancer (NSCLC) tumors with activating mutations in the epidermal growth factor receptor (EGFR) are highly responsive to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib and erlotinib, development of acquired resistance is almost inevitable. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "EGFR-tyrosine kinase (TK) inhibitors such as gefitinib and erlotinib are widely used in the treatment of non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Currently, five molecular targeted agents were approved for treatment of advanced NSCLC: Gefitinib, erlotinib and afatinib for positive EGFR mutation, crizotinib for positive echinoderm microtubule-associated protein-like 4 (EML4)-ALK translocation and bevacizumab. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib, gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced non-small-cell lung cancer (NSCLC) who harbor EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Small-molecule inhibitors of the EGF receptor's tyrosine kinase domain (TKIs), including gefitinib and erlotinib, have been widely used for treating NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "KEY RESULTS: Luteolin exerted significant anti-tumourigenic effects on the EGF receptor L858R/T790M mutation and erlotinib-resistant NSCLC both at the cellular and animal levels. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION AND IMPLICATIONS: Luteolin may be a potential candidate for NSCLC therapy, especially for treatment of patients with acquired erlotinib-resistant NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In this study, we evaluated the correlation between EGFR mutations and response to erlotinib in Chinese NSCLC patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We recruited 36 patients with stage IIIB/IV NSCLC who had failed first-line chemotherapy, and treated them with erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In conclusion, the presence of EGFR mutations could be a marker to predict the therapeutic efficacy of erlotinib and the prognosis in Chinese NSCLC patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We studied a broad subset of exon 20 insertion mutations, comparing in vitro TKI sensitivity with responses to gefitinib and erlotinib in NSCLC patients, and found that most are resistant to EGFR TKIs. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Unexpectedly, we find that EGFR-A763_Y764insFQEA is highly sensitive to EGFR TKIs in vitro, and patients whose NSCLCs harbor this mutation respond to erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: In the study, there were 123 patients who were diagnosed with advanced NSCLC in Zhejiang Province Cancer Hospital between January 2009 to October 2012, all of who were received gefitinib and erlotinib therapy after failure to chemotherapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVES: Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Eligible studies included randomized controlled trials with gefitinib and erlotinib in advanced NSCLC patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Treatment with EGFR TKIs gefitinib and erlotinib is associated with a significant increase in the risk of developing both all-grade and fatal ILD events in advanced NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The approval of pemetrexed and erlotinib by the FDA and the EMEA and the promising data with gefitinib have certainly shifted the pendulum towards maintenance therapy, however, the precise role for the treatment strategy of NSCLC in terms of a maintenance approach is far from being clear and additional studies are warranted to further clarify this option. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Patients with non-small cell lung cancer (NSCLC) who have activating epidermal growth factor receptor (EGFR) mutations benefit from treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), namely, gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We evaluated erlotinib and gefitinib as salvage treatments for NSCLC patients with brain metastases that failed to respond to radiotherapy in a retrospective study. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The 103 NSCLC patients who were treated with gefitinib or erlotinib for salvage treatment for brain metastases between January 2005 and December 2011 had overall objective response rates (ORR) of 11.7%, disease control rates (DCR) of 53.4%, 3.6 months of median progression-free survival (PFS), and 7.5 months of median survival. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Our retrospective data suggest a potential role for gefitinib and erlotinib in advanced NSCLC patients with brain metastases which have failed to respond to radiotherapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell lung cancer (NSCLC) because it is commonly employed after failure of another EGFR-TKI, gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: Medical records from 104 patients with NSCLC treated with erlotinib were retrospectively reviewed. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "RESULTS: There were no significant differences in erlotinib efficacy between EGFR-mutated NSCLC with gefitinib resistance and NSCLC with wild-type EGFR. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Erlotinib may be a therapeutic option for EGFR-mutated NSCLC with gefitinib resistance, as well as for NSCLC with wild-type EGFR. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Drugs directed against Epidermal Growth Factor Receptor (EGFR), namely tyrosine kinase inhibitors erlotinib and gefitinib, and anti-angiogenic agents, namely the anti-Vascular Endothelial Growth Factor (VEGF) antibody bevacizumab, have independently demonstrated clinical benefit in the treatment of patients with advanced non-small cell lung cancer (NSCLC), and are currently approved for use in clinical practice. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, respectively). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Drugs targeting mutant epidermal growth factor receptors, such as erlotinib and gefitinib, may provide more effective, safer and better tolerated treatment options compared with chemotherapy among appropriately selected patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The first-generation, reversible EGFR inhibitors erlotinib and gefitinib in the first-line setting provide superior progression-free survival and quality of life compared to conventional chemotherapy in NSCLC harboring activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Elderly patients affected by epidermal growth factor receptor (EGFR) mutated NSCLC benefit mostly from a tyrosine kinase inhibitor of EGFR (erlotinib, gefitinib) which is associated with a good toxicity profile. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVE: Few treatment options are available for advanced non-small cell lung cancer (NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Re-administration of TKI seems to be a potential therapeutic option for treatment of selected advanced NSCLC patients after failure of ge\ufb01tinib or erlotinib, especially for the patients with NSCLC who once responded from the prior TKI treatment. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: The study included 58 patients with advanced NSCLC who had sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, had baseline computed tomography (CT) scans available that revealed a measurable lung lesion, had at least 2 follow-up CT scans during TKI therapy, and had experienced volumetric tumor growth. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: We analyzed 1,431 NSCLC patients who were treated with either gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Activating mutation in exons 19 or 21 of epidermal growth factor receptor (EGFR) in non-small-cell lung cancers (NSCLC) are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Phase II trials and retrospective reviews for gefitinib and erlotinib demonstrate these agents may have a role in both the chemoprevention of brain metastases and, in combination with WBRT, treatment for non-small cell lung cancer (NSCLC) brain metastases. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Personalized therapy of advanced non-small cell lung cancer (NSCLC) has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Advanced NSCLC patients who benefited from prior Gefitinib therapy can benefit again either with the original drug Gefitinib or the alternative drug Erlotinib when a second TKI therapy is resumed. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: New molecular targeted agents are needed for patients with non-small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In particular, gefitinib and erlotinib have become the standard of care in patients harboring epidermal growth factor receptor mutations, while crizotinib showed an impressive efficacy in patients with ALK-positive NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The purpose of this study was to compare the efficacy of gefitinib and erlotinib for control of LMC in NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: This study suggested that erlotinib had better control rate for LMC in NSCLC than gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: In 56 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line erlotinib or gefitinib, tumor volumes of dominant lung lesions were measured on baseline and follow-up computed tomography, and were analyzed for association with survival. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: Common treatment modalities for non-small cell lung cancer (NSCLC) involve the EGF receptor-tyrosine kinase inhibitors (EGFR-TKIs) like gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: EGFR activating mutations (exons 18 to 21) and EML4-ALK rearrangement are clinically important markers able to select NSCLC patients which benefit from EGFR or ALK tyrosine kinase inhibitors (gefitinib, erlotinib, crizotinib). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Plasma DNA samples were obtained after discontinuation of gefitinib or erlotinib in 75 patients with non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "These trials showed promising efficacy in patients with EGFR-mutant NSCLC or enriched for clinical benefit from EGFR tyrosine kinase inhibitors gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non-small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung cancer (NSCLC), although erlotinib also has activity in wild-type disease. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We report the successful long-term maintenance treatment of a patient with EGFR wild-type NSCLC with gefitinib and later erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We describe the patient's disease course and treatment in the context of EGFR TKI therapy and the prognostic factors for long-term clinical outcomes of NSCLC, including the development of erlotinib-induced rash. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR-TKI), such as erlotinib or gefitinib, demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harboring activating mutations of the EGFR gene. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In this article, the authors analyzed data of erlotinib in NSCLC, focusing on its role in front-line therapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The study aimed to compare the effectiveness and prognosis of advanced NSCLC with gefitinib or erlotinib, as well as the cost-effectiveness ratio of the two drugs. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: For EGFR mutant advanced NSCLC patients, equal efficacy and survival benefit were observed in patients with gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Publisher: \u80cc\u666f\u4e0e\u76ee\u7684 \u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08non-small cell lung cancer, NSCLC\uff09\u9776\u5411\u6cbb\u7597\u8d8a\u6765\u8d8a\u53d7\u5230\u5173\u6ce8\uff0c\u5409\u975e\u66ff\u5c3c\u548c\u5384\u6d1b\u66ff\u5c3c\u5747\u88ab\u63a8\u8350\u7528\u4e8e\u5b58\u5728\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\u916a\u6c28\u9178\u6fc0\u9176\uff08epidermal growth factor receptor, EGFR\uff09\u57fa\u56e0\u7a81\u53d8\u7684\u665a\u671fNSCLC\u7684\u4e00\u7ebf\u6cbb\u7597\u3002\u672c\u7814\u7a76\u65e8\u5728\u5206\u6790\u6bd4\u8f83\u5409\u975e\u66ff\u5c3c\u548c\u5384\u6d1b\u66ff\u5c3c\u5728\u665a\u671fNSCLC\u7684\u7597\u6548\u548c\u751f\u5b58\u83b7\u76ca\uff0c\u4ee5\u53ca\u6cbb\u7597\u6210\u672c\u6548\u76ca\u3002 \u65b9\u6cd5 \u56de\u987e\u6027\u5206\u6790\u5e7f\u5dde\u533b\u4fdd\u5185\u768466\u4f8bEGFR\u7a81\u53d8\u578b\u7684NSCLC\u60a3\u8005\u3002\u89c2\u5bdf\u7597\u6548\u548c\u8bb0\u5f55\u4e0d\u826f\u53cd\u5e94\uff0c\u5b9a\u671f\u968f\u8bbf\u751f\u5b58\u9884\u540e\uff0c\u5e76\u8ffd\u8e2a\u6cbb\u7597\u8d39\u7528\u3002\u7ed3\u679c \u603b\u517166\u4f8b\u53ef\u8bc4\u4f30\u60a3\u8005\uff0c\u4e2d\u4f4d\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08progression-free survival, PFS\uff09\u4e3a15.0\u4e2a\u6708\u3002\u5176\u4e2d\u5409\u975e\u66ff\u5c3c49\u4f8b\uff0c\u5384\u6d1b\u66ff\u5c3c17\u4f8b\uff0c PFS\u5206\u522b\u4e3a17.5\u4e2a\u6708\u548c13.0\u4e2a\u6708\uff08P=0.459\uff09\u3002\u76ae\u75b9\u53d1\u751f\u7387\u5409\u975e\u66ff\u5c3c\u7ec4\u4e3a62.3% \uff0831/49\uff09\uff0c\u5384\u6d1b\u66ff\u5c3c\u7ec4\u4e3a94.1%\uff0816/17\uff09\u3002\u6210\u672c-\u6548\u76ca\u6bd4\u7387\uff08cost-effectiveness ratio, CER\uff09\u5409\u975e\u66ff\u5c3c\u7ec4\u4e3a3,027\u5143/\u6708\uff0c\u5384\u6d1b\u66ff\u5c3c\u7ec4\u4e3a6,800\u5143/\u6708\uff0c\u589e\u91cf\u6210\u672c-\u6548\u76ca\u6bd4\u7387\uff08incremental cost-effectiveness ratio, ICEA\uff09\u5384\u6d1b\u66ff\u5c3c\u4e3a\u5409\u975e\u66ff\u5c3c\u76842.25\u500d\u3002\u7ed3\u8bba EGFR\u7a81\u53d8\u7684\u665a\u671fNSCLC\u60a3\u8005\u6cbb\u7597\uff0c\u5409\u975e\u66ff\u5c3c\u548c\u5384\u6d1b\u66ff\u5c3c\u6709\u76f8\u4f3c\u7684\u7597\u6548\u548c\u751f\u5b58\u83b7\u76ca\uff0c\u524d\u8005\u4e0d\u826f\u53cd\u5e94\u53ef\u80fd\u8f83\u4e3a\u8f7b\u5fae\u3002\u5e7f\u5dde\u533b\u4fdd\u4e0b\uff0c\u5409\u975e\u66ff\u5c3c\u6210\u672c-\u6548\u76ca\u6bd4\u7387\u7a0d\u4f18\u3002 DOI: 10.3779/j.issn.1009-3419.2013.04.06 PMID: 23601301 [PubMed - indexed for MEDLINE]  OBJECTIVE: Erlotinib has been reported to be useful for treatment of non-small-cell lung cancer harboring mutation of the epidermal growth factor receptor gene EGFR-mt. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: We retrospectively screened 160 NSCLC patients harboring EGFR mutations, who had received either gefitinib, or erlotinib between 1992 and 2011. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: The results show that maintenance therapy with erlotinib or gefitinib produces a significant PFS and OS benefit for unselected patients with advanced NSCLC compared with placebo or observation. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Tyrosine kinase inhibitors, such as erlotinib or gefitinib, have demonstrated promising results in patients with advanced NSCLC that harbor EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Subsequently EGFR TKIs (gefitinib, erlotinib or afatinib) or monoclonal antibody cetuximab were combined respectively with the c-MET-specific TKI su11274 in NSCLC cell lines. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The first two reversible EGFR-TKIs, erlotinib and gefitinib, are approved for use in the first-line setting in patients with known EGFR-activating mutations and in the second- and third-line settings for all NSCLC patients. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Erlotinib is an orally administered small-molecule inhibitor of EGF receptor (EGFR) tyrosine kinase that is approved for the treatment of non-small-cell lung cancer (NSCLC) and pancreatic cancer. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Erlotinib was first approved for the treatment of unselected NSCLC patients with advanced disease after failure of at least one prior chemotherapy regimen, and it was subsequently demonstrated to also confer a significant clinical benefit as maintenance therapy after first-line platinum-based chemotherapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Results from recently published, randomized Phase III trials showed that first-line erlotinib significantly prolongs progression-free survival in patients with advanced EGFR mutation-positive NSCLC with favorable tolerability, compared with standard chemotherapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In lung cancer, 10-15% of NSCLC contain activating mutations in the EGFR kinase conferring hypersensitivity to the oral TKIs gefitinib and erlotinib, have been demonstrated to be important predictive factors when selecting patients to be treated with these two agents. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " INTRODUCTION: : Despite an initial dramatic response to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, the majority of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations develop acquired resistance. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: : Erlotinib-resistant PC-9ER cells were generated from PC-9 NSCLC cells, which harbor an EGFR-activating mutation, and used in this study. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line treatment for this patient group. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of the epidermal growth factor receptor gene (EGFR-mt). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Here, we conducted a retrospective analysis of AEs and drug efficacy in patients with NSCLC whose EGFR mutation status had been confirmed and who all received 250 mg gefitinib or 150 mg erlotinib once daily. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "However, this study has several limitations as of the nature of retrospective design; our data suggest that gefitinib and erlotinib might have almost equal efficacy for patients with EGFR-wt NSCLC, as is the case for patients with EGFR-mt tumors, although erlotinib appears to have higher toxicity than gefitinib at each approved dose. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Using real-time RT-PCR to analyze the EGFR mRNA expression level in EGFR wild-type non-small cell lung cancer (NSCLC) cells; MTT analysis detected the cytotoxicity for NSCLC cells to Erlotinib; Western blot analysis examined the mutant situations and the downstream signaling protein phosphorylation level in EGFR-mutant NSCLC cells with the treatment of Erlotinib or/and PI3K inhibitor, LY294002. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "RESULTS: In the EGFR wild-type NSCLC cells, the expression level of EGFR mRNA varied dramatically and all the cells showed resistant to Erlotinib; In the EGFR-mutant cells, HCC827 and H1650 (the same activating-mutation type), HCC827 cells were Erlotinib-sensitive as well as H1650 demonstrated primary relative resistance. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: EGFR wild-type NSCLC cells were resistant to Erlotinib no matter of how EGFR mRNA expression level. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The PTEN loss and activation of AKT signaling pathway contributed to Erlotinib resistance in EGFR-mutant NSCLC cell line H1650. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Treatment of non-small cell lung cancer (NSCLC) with drugs targeting the epidermal growth factor receptor (EGFR), e.g., gefitinib and erlotinib, will eventually fail because of the development of secondary mutations such as T790M in EGFR. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Growing clinical evidence supports a personalized approach to non-small cell lung cancer (NSCLC) treatment, and clinical trials in advanced disease have shown the value of testing for epidermal growth factor receptor gene (EGFR) mutations prior to first-line therapy with erlotinib or gefitinib and testing for anaplastic lymphoma kinase gene (ALK) rearrangements prior to therapy with crizotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: Data from 88 NSCLC patients receiving gefitinib (250 mg, daily [qd]), erlotinib (150 mg, qd), and ZD6474 (100 mg, qd) in three clinical trials (IRESSA registration clinical trial, TRUST study, ZD6474 study) during November 2003 to June 2005 were retrospectively analyzed. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Non-small cell lung cancer(NSCLC)patients with activating mutations of the epidermal growth factor receptor(EGFR)gene have shown a dramatic response to EGFR tyrosine kinase inhibitors(EGFR-TKI)such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Erlotinib was the first target agent approved for the treatment of NSCLC in second- and third line, in patients unselected for EGFR mutations; gefitinib was the first EGFR tyrosine kinase inhibitor approved for the treatment of NSCLC in all lines of setting in patients harbouring EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: VeriStrat(\u00ae) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib and afatinib, have been investigated in the treatment of non-small cell lung cancer (NSCLC), and to date a large amount of clinical data are available. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This review will summarize the current evidence that strongly support the hypothesis that gefitinib, erlotinib and afatinib are ideal drugs for NSCLC patients carrying EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In particular, the tyrosine- kinase inhibitors (TKIs) gefitinib and erlotinib targeting the epidermal growth factor receptor (EGFR) have been approved for the treatment of non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: The Taiwan Cancer Registry and the National Health Insurance claim databases were searched for newly diagnosed patients with NSCLC from 2004 to 2007 who received gefitinib or erlotinib as third-line therapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Gefitinib and erlotinib had similar efficacies as salvage therapy for advanced NSCLC in Taiwan. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Pretreatment CEA and CYFRA 21-1 were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: h-CEA and l-CYFRA 21-1 may be prognostic and predictive serum markers for higher response and longer survival in patients with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with unknown EGFR mutation status or patients with squamous cell carcinoma. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Gefitinib and erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), are widely used anticancer drugs for patients with non-small cell lung cancer (NSCLC), especially for those with EGFR-activating mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: We performed this study to explore the association of computed tomography (CT) findings with outcomes of patients with non-small-cell lung cancer (NSCLC) treated with tyrosin kinase inhibitor (TKI) such as gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Epidermal growth factor receptor (EGFR)--tyrosine kinase inhibitors (TKI) like erlotinib and gefitinib have been approved as monotherapy for the treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The EGFR inhibitors gefitinib and erlotinib have a definite activity in brain metastases from NSCLC with activating EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: We examined 15 Japanese patients with NSCLC and CNS metastases with epidermal growth factor receptor gene mutations who received CSF examinations during epidermal growth factor receptor-tyrosine kinase inhibitors treatment (250 mg daily gefitinib or 150 mg daily erlotinib). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "OS has been the principal endpoint influencing regulatory decisions regarding targeted therapies for metastatic NSCLC, including the vascular endothelial growth factor monoclonal antibody bevacizumab in the frontline setting and the epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib in patients after prior treatment. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The objective of this review was to assess the predictive value of skin rash for outcome in patients with NSCLC treated with erlotinib and gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Currently, only erlotinib is offered as a third-line option in unselected nsclc patients after failure of first- and second-line chemotherapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " The oral tyrosine kinase inhibitors of epidermal growth factor, erlotinib and gefitinib, are active in the treatment of non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In this study, we report a patient with NSCLC who remains responsive to erlotinib treatment following successful rechallenge with a reduced dose of erlonitib after presenting with severe degree of leukoclastic vasculitis. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " INTRODUCTION: This retrospective study was undertaken to investigate the impact of specific mutant KRAS on clinical outcome to either gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) in patients with EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Our aim was to determine the correlations of these surrogates with survival in the treatment of advanced non-small-cell lung cancer (ANSCLC) with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) gefitinib and erlotinib have shown dramatic response rate (RR) and significant prolongation of progression-free survival (PFS) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: This retrospective study was undertaken to investigate the impact of initial gefitinib or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of central nervous system (CNS) progression in advanced non-small cell lung cancer (NSCLC) with EGFR mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "EXPERIMENTAL DESIGN: Patients with stage IV or relapsed NSCLC with a sensitizing EGFR mutation initially treated with gefitinib, erlotinib, or chemotherapy were identified. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "If validated, our results suggest that gefitinib and erlotinib may have a role in the chemoprevention of CNS metastases from NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " While most patients with metastatic non-small cell lung cancer (NSCLC) containing sensitizing mutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resistance to these agents. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non-small-cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In this article, we updated the evidence of erlotinib in treating advanced NSCLC by adding new results of RCTs published between January 2011 and May 2012 into a pooled analysis which had been published in 2011. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "NSCLC patients with epidermal growth factor receptor (EGFR) gene mutations have shown a dramatic response to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Several molecular aberrations have been identified in NSCLC, with subsequent development of drugs targeted to these aberrations; gefitinib, erlotinib, and cetuximab for the treatment of NSCLC harboring epidermal growth factor receptor mutation or overexpression, and crizotinib for the treatment of NSCLC with the EML4-ALK fusion translocation oncogene being some examples. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "There was also a considerable difference in the type and efficacy of salvage chemotherapeutic regimens between the two groups: salvage regimens with irinotecan, platinum, or taxanes were commonly used with relatively high objective responses in the SCLC regimen group, whereas frequently used agents in the NSCLC regimen group such as pemetrexed, gefitinib, or erlotinib were associated with no objective response. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Non-small-cell lung cancer (nsclc) tumours with activating mutations of the epidermal growth factor receptor (efgr) tyrosine kinase are highly sensitized to the effects of oral tyrosine kinase inhibitors such as gefitinib and erlotinib, suggesting the possibility of targeted treatment of nsclc based on EFGR mutation status. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib show promising therapeutic effects in patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Currently available agents with established role in NSCLC include the anti-EGFR tyrosine-kinase inhibitors (TKIs) erlotinib/gefitinib and the anti-VEGF monoclonal antibody bevacizumab. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Patients with advanced non-small-cell lung cancer (NSCLC) and somatic activating mutations of the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene represent a biologically distinct disease entity that shows exquisite sensitivity to the reversible EGFR-TK inhibitors (-TKIs) gefitinib or erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In the last decade, the tyrosine kinase (TK) domain of the EGFR was identified in NSCLC patients, and it has responded very well with a dramatic clinical improvement to TK inhibitors such are gefitinib and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Molecular target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In NSCLC activating somatic mutations in exons encoding the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene have been found to be predictive of a response to treatment with tyrosine kinase inhibitors (TKI), erlotinib or gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Results of the phase III study JBR.21 proved the clinical efficacy of erlotinib-based regimens as second- or third-line treatment of advanced NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We analyze efficacy of treatment with erlotinib in patients suffering from advanced stage NSCLC who participated in the multicentre, international phase IV study - MO 18109 TRUST (expanded access clinical program of Tarceva\u2122 in patients with advanced stage IIIB/IV NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Results of the TRUST study in the Polish population confirmed the efficacy of erlotinib in advanced NSCLC after failure of prior platinum-based chemotherapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib have provided substantial benefits to patients with advanced non-small cell lung cancer (NSCLC). ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Patients with advanced NSCLC who had received prior platinum-doublet chemotherapy and/or erlotinib/gefitinib therapy, or who were ineligible for, or not amenable to, treatment with established therapies, received oral afatinib once daily. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Advanced non-small-cell lung cancer (NSCLC) harboring activating mutations of epidermal growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs), namely erlotinib and gefitinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Eligible studies included published randomized controlled trials in which erlotinib or gefitinib (alone or with chemotherapy) were compared with standard therapy in 1260 patients with EGFR-mutated NSCLCs who were included in 13 trials. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "NSCLCs harboring EGFR mutations derive greater benefit from erlotinib or gefitinib than from chemotherapy. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Erlotinib, the epidermal growth factor receptor tyrosine kinase inhibitor, and the intra-venous vinflunine vinca alkaloid microtubule inhibitor have been shown to be effective in the setting of non-small-cell lung cancer (NSCLC) palliative patients with acceptable toxicities. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: Patients with unresectable stage IIIB or stage IV NSCLC who failed one or two previous chemotherapy regimens were treated with flat doses of oral vinflunine from day 1 to day 5 and from day 8 to day 12 every 3\u00a0weeks and erlotinib daily on a continuous basis. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Erlotinib is approved for the treatment of all patients with advanced non-small-cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We compared the efficacy of cabozantinib alone or in combination with erlotinib versus erlotinib alone in patients with EGFR wild-type NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "INTERPRETATION: Despite its small sample size, this trial showed that, in patients with EGFR wild-type NSCLC, cabozantinib alone or combined with erlotinib has clinically meaningful, superior efficacy to that of erlotinib alone, with additional toxicity that was generally manageable. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "RESULTS: Between January 2010 and June 2014, a total of 24 EGFR-mutant NSCLC patients who had been previously treated with EGFR-TKIs (gefitinib, erlotinib, and/or afatinib) received EGFR-TKI rechallenge with bevacizumab. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "However, the benefit of ARBs on OS disappeared in the multivariate analysis.The use of ARBs during erlotinib treatment may prolong OS of patients with metastatic NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We aimed to compare the efficacy and safety of the combination of erlotinib and bevacizumab compared with erlotinib alone in patients with non-squamous NSCLC with activating EGFR mutation-positive disease. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: In this open-label, randomised, multicentre, phase 2 study, patients from 30 centres across Japan with stage IIIB/IV or recurrent non-squamous NSCLC with activating EGFR mutations, Eastern Cooperative Oncology Group performance status 0 or 1, and no previous chemotherapy for advanced disease received erlotinib 150 mg/day plus bevacizumab 15 mg/kg every 3 weeks or erlotinib 150 mg/day monotherapy as a first-line therapy until disease progression or unacceptable toxicity. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "INTERPRETATION: Erlotinib plus bevacizumab combination could be a new first-line regimen in EGFR mutation-positive NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Combining targeted therapy has been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We thus performed a meta-analysis of randomized controlled trials to compare the efficacy and safety of combining targeted therapy versus erlotinib alone as second-line treatment for advanced NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: With the available evidence, combining targeted therapy seems superior over erlotinib monotherapy as second-line treatment for advanced NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Trials comparing these agents with other chemotherapy, evaluating the addition of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) to chemotherapy or the addition of another targeted agent to erlotinib or gefitinib have all failed to demonstrate an improvement in overall survival for patients with NSCLC. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "drug": "erlotinib", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We herein report mature data of a phase I/II study testing the addition of cetuximab to induction vinorelbine/cisplatin (NP) followed by concurrent cetuximab NP and thoracic radiation in patients with unresectable stage III NSCLC. ", "drug": "vinorelbine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The phase III FLEX trial demonstrated an increase in survival for cisplatin/vinorelbine plus cetuximab compared to chemotherapy alone in patients with advanced EGFR-expressing NSCLC. ", "drug": "vinorelbine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "drug": "vinorelbine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: This phase II study evaluated the efficacy of gefitinib 250 mg once daily in combination with thoracic radiotherapy (66 Gy in 6.5 weeks, 2 Gy/day, 5 fractions/week) followed by consolidation chemotherapy (IV cisplatin and vinorelbine) as first line treatment in a population of unselected stage IIIB NSCLC patients according to EGFR mutation status. ", "drug": "vinorelbine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The antitumor efficacy of different treatment sequences using vinorelbine (VNB) and gefitinib (GEF) was investigated both in vitro and in vivo in non-small cell lung cancer (NSCLC) cell lines with the rationale of potentially translating these findings into the clinical setting. ", "drug": "vinorelbine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "drug": "vinorelbine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "drug": "vinorelbine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVE: The aim of this study was to evaluate efficacy and safety of first-line treatment with bevacizumab, cisplatin and vinorelbine and bevacizumab maintenance in non-squamous, non-small cell lung cancer (NSCLC). ", "drug": "vinorelbine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Pre-treatment samples from 65 locally advanced or oligometastatic NSCLC patients, who underwent uniform induction chemotherapy with paclitaxel and platinum followed by radiochemotherapy with vinorelbine and platinum were retrospectively analysed by immunohistochemistry. ", "drug": "vinorelbine", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "drug": "Second-Line Chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In ALK-translocated NSCLC, a Phase III trial demonstrated the superiority of a multi-target TKI, including ALK, in terms of progression-free survival, response rate and toxicity profile when compared to standard second-line chemotherapy. ", "drug": "Second-Line Chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: Disease progression remains the major challenge in the management of advanced (stage IIIb or IV) non-small cell lung cancer (NSCLC) after the failure of first-line or second-line chemotherapy, or even of targeted therapies such as gefitinib. ", "drug": "Second-Line Chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Currently, only erlotinib is offered as a third-line option in unselected nsclc patients after failure of first- and second-line chemotherapy. ", "drug": "Second-Line Chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Evidence about its efficacy in addition to second-line chemotherapy in non-small cell lung cancer (NSCLC) has been produced by two large randomized phase III clinical trials (LUME-Lung 1 and LUME-Lung 2), conducted in patients with pretreated NSCLC, without major risk factors for bleeding. ", "drug": "Second-Line Chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In advanced NSCLC, PD1/PD-L1\u00a0inhibitors are more effective than second-line chemotherapy. ", "drug": "Second-Line Chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: The aim of this retrospective study was to investigate the anticancer effect and toxicity of weekly administered nab-paclitaxel as a second-line chemotherapy in elderly patients with relapsed squamous non-small-cell lung cancer (NSCLC). ", "drug": "Second-Line Chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: Second-line chemotherapy of advanced non-small cell lung cancer (NSCLC) with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "drug": "Second-Line Chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Only selected NSCLC patients could benefit from second-line chemotherapy. ", "drug": "Second-Line Chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Here we describe 2 cases of infiltrative pneumonitis induced by docetaxel as second-line chemotherapy in advanced NSCLC. ", "drug": "Second-Line Chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Two patients with advanced NSCLC were treated with weekly docetaxel as second-line chemotherapy. ", "drug": "Second-Line Chemotherapy", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This review provides a summary of currently available, clinically relevant data on the incidence of hypertension with VEGF-targeted antibodies and multitargeted antiangiogenic TKIs in advanced NSCLC and discusses the potential predictive role of hypertension on antiangiogenic therapy in such patients. ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": " There is no cure for non-small-cell lung cancer (NSCLC) or pulmonary arterial hypertension (PAH). ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: The addition of bevacizumab to therapy in advanced NSCLC did significantly increase the risk of proteinuria, hypertension, and hemorrhagic events but not arterial/venous thromboembolic events, gastrointestinal perforation, or fatal adverse events. ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": " AIM: A study was conducted to determine the overall risk and incidence of hypertension with bevacizumab in non-small-cell lung cancer (NSCLC) patients. ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "The overall incidences of all-grade and high-grade hypertension in NSCLC patients were 19.55% (95% CI 10.17%-34.3%) and 6.95% (95% CI 5.81%-8.30%). ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Bevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: A meta-analysis of published data was conducted to investigate the overall risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer (NSCLC) who were receiving vandetanib. ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "METHODS: A computerized search through electronic databases, including PubMed and Embase (until Dec 2014), was performed to obtain eligible randomized controlled trials (RCTs) that compared hypertension and/or QTc prolongation profile of vandetanib alone or plus chemotherapy with control groups (placebo, single targeted therapy, chemotherapy, or a combination of them) in patients with advanced NSCLC. ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "A significant increase in risk was observed for all-grade hypertension (RR 5.58; 95% CI 4.16 to 7.48; P\u2009<\u20090.00001) and grade \u22653 hypertension (RR 4.79; 95% CI 2.31 to 9.93; P\u2009<\u20090.0001) in advanced NSCLC patients who were receiving vandetanib compared with the controls. ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Current evidence showed that significant risks in developing hypertension and QTc prolongation exist in advanced NSCLC patients who were receiving vandetanib. ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "The addition of bevacizumab to chemotherapy or erlotinib can significantly improve PFS and ORR both in first- and second-line treatments of advanced NSCLC, with an acceptable risk of bleeding events, hypertension, proteinuria, and rash. ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": " A 60-year-old woman with hypertension, dyslipidemia, and 35-pack-year smoking history is referred for treatment of advanced non-small-cell lung cancer (NSCLC). ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "This review provides a summary of currently available, clinically relevant data on the incidence of hypertension with VEGF-targeted antibodies and multitargeted antiangiogenic TKIs in advanced NSCLC and discusses the potential predictive role of hypertension on antiangiogenic therapy in such patients. ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": " BACKGROUND: In non-small cell lung cancer (NSCLC), interstitial hypertension is a barrier to chemotherapy delivery, and is mediated by platelet derived growth factor receptor (PDGFR). ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "Subgroup analysis demonstrated that the pooled incidences of all-grade and high-grade hypertension were 21.8% [95% CI, 15-30.5%] and 7.6% (95% CI, 2.8-18.8%), respectively, among non-small-cell lung cancer (NSCLC) patients, and 32.1% (95% CI: 27.3-37.3%) and 8.8% (5.9%-12.9%), respectively, among MTC patients, and 15.4 (95% CI: 3.2-33.7%) and 3.4% (95% CI: 1%-11.1%) respectively, among non-MTC/NSCLC tumors patients. ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "Adverse events were generally consistent with previous NSCLC studies of vandetanib 300 mg; common events occurring with a greater frequency in the vandetanib arm versus placebo included diarrhea (46% v 11%), rash (42% v 11%), and hypertension (26% v 3%). ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "Accumulated safety data with bevacizumab in NSCLC shows that patients are at risk for hemorrhage, venous thromboembolism, hypertension, and proteinuria. ", "drug": "hypertension", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "The present work evaluated the in vitro effects of chitosan cross-linked \u03b3-poly(glutamic acid) (\u03b3-PGA) nanoparticles (Nps) loaded with docetaxel (DTXL) and decorated with Cetuximab (CET), targeted to EGFR over-expressing non-small-cell-lung-cancer (NSCLC) cells (A549). ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Frequency and functional activity of Treg was analyzed in 31 NSCLC stage IB-IIIA patients treated by neoadjuvant Cetuximab/Docetaxel/Cisplatin prior to surgery. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Crizotinib improved progression-free survival compared to second-line chemotherapy with docetaxel or pemetrexed in patients with advanced anaplastic lymphoma kinase-positive NSCLC. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Selumetinib added to docetaxel has improved outcome compared with docetaxel in a randomized phase II trial in patients with advanced KRAS-mutant NSCLC and this combination is currently studied in a phase III trial. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Nintedanib added to docetaxel improved progression-free survival in the second-line therapy of patients with advanced NSCLC but many other angiogenesis inhibitors failed to improve clinical outcome in phase III trials. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In SD patients with advanced non-small cell lung cancer (NSCLC) who have already received four cycles of first-line chemotherapy with platinum agents plus a third-generation agent (gemcitabine, vinorelbine, docetaxel or paclitaxel) or pemetrexed, the continuation of the original treatment is not recommended according to the American Society of Clinical Oncology (ASCO) guidelines. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " This open label, single arm phase II study was designed to evaluate the efficacy and safety of the addition of cetuximab to first line chemotherapy with carboplatin and weekly docetaxel in patients with advanced non small-cell lung cancer (NSCLC). ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "From February 2007 to December 2008 74 patients with NSCLC (stage IIIB and IV), ECOG PS \u22642 and no prior systemic chemotherapy were enrolled and treated with carboplatin (area under the curve=5 on day 1) and docetaxel (35 mg/m(2) on days 1, 8, and 15). ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Results from this phase II study suggest that the addition of cetuximab to first-line doublet carboplatin and weekly docetaxel results in a considerable clinical efficacy with an acceptable toxicity profile for patients with advanced or metastatic NSCLC. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: Docetaxel and gefitinib play key roles in the treatment of non-small-cell lung cancer (NSCLC), and their combination could be of interest. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "OBJECTIVES: To appraise the clinical effectiveness and cost-effectiveness of erlotinib [Tarceva(\u00ae), Roche (UK) Ltd] and gefitinib (IRESSA(\u00ae), AstraZeneca) compared with each other, docetaxel or best supportive care (BSC) for the treatment of NSCLC after disease progression following prior chemotherapy. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The present practice review of tki use for second- and third-line treatment in EGFR wild-type nsclc also compares clinical outcomes for tki and single-agent docetaxel as second-line treatment. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: In our study cohort, second-line therapy for EGFR wild-type nsclc with tki (compared with docetaxel) was associated with statistically better pfs and efs and noninferior os. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in the presence of classical EGFR mutations, whereas in the EGFR(WT) population, a similar efficacy to docetaxel or pemetrexed in terms of survival has been demonstrated. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Patients with advanced NSCLC with a PS of 2 or 3 were enrolled into a multicenter randomized trial: arm A, gefitinib; arm B, gemcitabine; and arm C, docetaxel. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In pretreated NSCLC, EGFR TKIs are considered more effective than standard monotherapy with cytotoxics in presence of classical EGFR mutations, whereas in the EGFR wild-type population, a similar efficacy to docetaxel or pemetrexed in term of survival has been demonstrated. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In conclusion, the combination of docetaxel and gefitinib generated synergistic effects in EGFR-TKI-sensitive cells and antagonistic effects in EGFR-TKI-primary and acquired resistant cells, suggesting that EGFR-TKIs, combined with docetaxel, may be beneficial to NSCLC patients with EGFR mutations. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Using the tetrazolium colorimetric assay and classical isobole method, we investigated the combination effects of 6 gefitinib-chemotherapeutic doublets (gefitinib/cisplatin, gemcitabine, pemetrexed, paclitaxel, docetaxel, or vinorelbine) in a panel of 15 NSCLC cell lines. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for advanced non-small cell lung cancer (NSCLC) patients with disease progression. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "This review assessed QOL outcomes of approved, guideline-supported 2L chemotherapy with docetaxel, erlotinib, gefitinib, and pemetrexed in advanced NSCLC. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: The combination effects of gefitinib with three antimicrotubule agents (AMTAs), paclitaxel, docetaxel or vinorelbine, or with gemcitabine were tested in 17 NSCLC cell lines using the tetrazolium colorimetric assay and classical isobole method. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: \u2003 Gefitinib is a dominant cost saving strategy compared with docetaxel for the second-line treatment of advanced NSCLC from the Thai payer perspective. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "INTERPRETATION: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "On these bases, the combination of docetaxel and nintedanib can be considered a new option for the second-line treatment for patients with advanced NSCLC with adenocarcinoma histology. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " OBJECTIVES: LUME-Lung 1 was a randomized, placebo-controlled, Phase III trial investigating nintedanib+docetaxel versus placebo+docetaxel in patients with advanced NSCLC progressing after first-line chemotherapy. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In the EU, nintedanib in combination with docetaxel is indicated for adults with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Nintedanib in combination with docetaxel relative to placebo plus docetaxel significantly prolonged progression-free survival (PFS), but did not increase overall survival (OS), in the overall population of patients with advanced NSCLC in the phase III LUME-Lung 1 study. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "To conclude, nintedanib in combination with docetaxel is an effective treatment option for patients with advanced NSCLC of adenocarcinoma histology after first-line chemotherapy. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "PATIENTS AND METHODS: Eligible patients with histologically confirmed KRAS-mutant NSCLC previously treated with one prior platinum-based chemotherapy were randomly assigned in a ratio of 2 : 1 to trametinib (2 mg orally once daily) or docetaxel (75 mg/m(2) i.v. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "RESULTS: One hundred and twenty-nine patients with KRAS-mutant NSCLC were randomized; of which, 86 patients received trametinib and 43 received docetaxel. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: Trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRAS-mutant-positive NSCLC. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: To evaluate a 3-drug combination of carboplatin, docetaxel and bevacizumab as a front-line chemotherapy for patients with advanced non-squamous non-small cell carcinoma (NSCLC), a single arm phase II study was conducted. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "METHODS: Patients with stage IIIB/IV or postoperative recurrent non-squamous NSCLC were treated with carboplatin (targeted area under the curve of 6 mg h/L), docetaxel (60 mg/m(2)), and bevacizumab (15 mg/kg) on day 1, repeated every 3 weeks for 4 to 6 cycles, followed by maintenance with bevacizumab every 3 weeks until disease progression or occurrence of predefined toxicity. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "INTERPRETATION: Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "However, these advances, did not allow an improvement of the same endpoints in the management of NSCLC with squamous cell histology (SCC), where until very recently, docetaxel in monotherapy remained as a corner stone treatment for the second line, although associated with an unfavorable toxicity profile. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: In EGFR-mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Food and Drug Administration (FDA) approved ramucirumab for use in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Expert opinion: The addition of ramucirumab to docetaxel in the treatment of patients with metastatic NSCLC who have progressed on or after platinum-based chemotherapy confers a 1.4-month improvement in overall survival, with an acceptable toxicity profile. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The potential impact of the approval of the programmed death receptor-1 (PD-1)-blocking antibody nivolumab or pembrolizumab on the use of ramucirumab plus docetaxel in advanced NSCLC patient population is uncertain in clinical practice. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In order to improve overall outcomes for patients with advanced NSCLC, both ramucirumab plus docetaxel and the PD-1-blocking antibody should be used in any treatment line. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Randomised trials over the past 10-15\u00a0years have established pemetrexed (non-squamous histology), docetaxel, erlotinib and gefitinib as approved second-line agents in NSCLC without targetable driver mutations or rearrangements. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In several large, randomized studies, PD-1/PD-L1 inhibitors have produced significant improvements in overall survival compared with single-agent docetaxel delivered in the second-line setting, effectively establishing a new standard of care in NSCLC. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: The current analysis of data indicates that the benefit from PD-1 inhibitors versus docetaxel in second line treatment of NSCLC is limited to the PD-L1>1% subpopulation. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "The phase II/III randomized KEYNOTE-010 trial demonstrated that pembrolizumab improved OS versus docetaxel in patients with previously treated NSCLC. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " In non-small cell lung cancer (NSCLC), the first immune checkpoint inhibitor to be approved by the US Food and Drug Administration was nivolumab, based on a survival advantage over docetaxel in recurrent squamous NSCLC, a difficult-to-treat histology. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Among these, nivolumab demonstrated a survival benefit versus docetaxel in refractory squamous NSCLC, reporting 41% reduction in risk of death (median overall survival: 9.2 versus 6.0 months; objective response rate: 20% versus 9%), and better safety profile than standard-of-care chemotherapy (grade 3-4 adverse events: 7% versus 55%). ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Areas covered: We searched Medline, Embase, Scopus and Cochrane Library for randomized phase III trials that evaluated docetaxel in various clinical settings of NSCLC and for meta-analyses of such trials and we present all relevant data regarding the pharmacology and clinical use of docetaxel in NSCLC. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Expert commentary: Despite its diminishing role, docetaxel in combination with novel targeted agents remains an important option of the therapeutic armamentarium in advanced NSCLC. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: In patients with advanced NSCLC pretreated with docetaxel/gemcitabine, the combination of pemetrexed/cisplatin is associated with increased OS and is better tolerated than the combination of irinotecan/cisplatin and should be considered as a valid therapeutic option for platinum-naive, previously treated patients. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "CONCLUSIONS: Response to cabazitaxel in NSCLC was not as robust as seen in prostate cancer and not superior to currently used agents such as docetaxel, pemetrexed, and erlotinib. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: Second-line chemotherapy of advanced non-small cell lung cancer (NSCLC) with docetaxel or pemetrexed allows to achieve objective response rate only in 5-10 % of patients. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Using HRM-PCR technique, we evaluated the -2166C>T SNP of STMN1 gene in DNA from peripheral blood leucocytes of 54 advanced NSCLC patients treated in second-line monotherapy with docetaxel or paclitaxel. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Docetaxel, a taxane chemotherapy drug widely used in the treatment of many types of solid tumors including non-small cell lung cancer (NSCLC), rarely causes infiltrative pneumonitis. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Here we describe 2 cases of infiltrative pneumonitis induced by docetaxel as second-line chemotherapy in advanced NSCLC. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "MATERIALS AND METHODS: Two patients with advanced NSCLC were treated with weekly docetaxel as second-line chemotherapy. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "Docetaxel and paclitaxel as single agents have also shown efficacy in the second-line setting in advanced/metastatic NSCLC. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": "TUBB3 expression may be a predictive marker for chemoresistance to docetaxel in NSCLC with postoperative recurrent disease. ", "drug": "docetaxel", "polarity": 1, "disease": "NSCLC"}, {"orig_sen": " Several randomized controlled clinical trials have compared therapy with or without thalidomide in the treatment of advanced non-small cell lung cancer (NSCLC). ", "drug": "thalidomide", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "We carried out a meta-analysis to determine the efficacy and safety of thalidomide-based therapy in patients with advanced NSCLC. ", "drug": "thalidomide", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "For this meta-analysis, we selected randomized clinical trials that compared thalidomide in combination with other therapy or other therapy alone in patients with advanced NSCLC. ", "drug": "thalidomide", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "The addition of thalidomide to other therapy did not improve survival and tumor response in patients with advanced NSCLC, and thalidomide-based therapy was associated with more grade 3/4 dizziness and constipation. ", "drug": "thalidomide", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": " PURPOSE: The primary objective of this study was to compare the survival of patients with unresectable stage III non-small-cell lung cancer (NSCLC) treated with combined chemoradiotherapy with or without thalidomide. ", "drug": "thalidomide", "polarity": 0, "disease": "NSCLC"}, {"orig_sen": "CONCLUSION: The addition of thalidomide to chemoradiotherapy increased toxicities but did not improve survival in patients with locally advanced NSCLC. ", "drug": "thalidomide", "polarity": 0, "disease": "NSCLC"}]